Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

Articles published in
J Hepatol
    September 2021
  1. CHEN Q, Wang H, Li Z, Li F, et al
    Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.
    J Hepatol. 2021 Sep 9. pii: S0168-8278(21)02025.
    >> Share

  2. DAI CY, Yeh ML, Yu ML
    An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously.
    J Hepatol. 2021 Sep 4. pii: S0168-8278(21)02021.
    >> Share

  3. DING ZY, Li GX, Shu C, Yin P, et al
    Reply to: Comments on "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
    J Hepatol. 2021;75:742-744.
    >> Share

  4. LUO MS, Huang GJ
    Letter regarding "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
    J Hepatol. 2021;75:737-739.
    >> Share

  5. SINGH A, Premkumar M, Singh V
    Liver injury in COVID-19 - The culprit may not be COVID-19!
    J Hepatol. 2021;75:739-740.
    >> Share

  6. MCCONNELL MJ, Kawaguchi N, Kondo R, Sonzogni A, et al
    Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.
    J Hepatol. 2021;75:647-658.
    >> Share

    August 2021
  7. WANG H, Zhang S, Zhang Y, Jia J, et al
    TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
    J Hepatol. 2021 Aug 28. pii: S0168-8278(21)02016.
    >> Share

  8. DAI CY, Chuang WL, Yu ML
    A prospective study in predicting portal thrombosis in cirrhosis: Some Issues.
    J Hepatol. 2021 Aug 27. pii: S0168-8278(21)02010.
    >> Share

  9. RICKE J, Schinner R, Seidensticker M, Gasbarrini A, et al
    Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
    J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02003.
    >> Share

  10. BLOOM P, Tapper EB, Young VB, Lok AS, et al
    Microbiome Therapeutics for Hepatic Encephalopathy.
    J Hepatol. 2021 Aug 25. pii: S0168-8278(21)01998.
    >> Share

  11. WANG H, Zhang H, Wang Y, Brown ZJ, et al
    Regulatory T cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Aug 4. pii: S0168-8278(21)01962.
    >> Share

  12. WANG J, Hou Z, Liu J, Gu Y, et al
    Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
    J Hepatol. 2021;75:439-441.
    >> Share

    July 2021
  13. TORGERSEN J, Newcomb CW, Carbonari DM, Rentsch CT, et al
    Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01950.
    >> Share

  14. TURON F, Driever EG, Baiges A, Cerda E, et al
    Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01946.
    >> Share

  15. CARPINO G, Cardinale V, Di Giamberardino A, Overi D, et al
    Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jul 27. pii: S0168-8278(21)01947.
    >> Share

  16. GALLE PR, Abou-Alfa G
    Decision making in systemic therapy of hepatocellular carcinoma: should we pay attention to disease etiology?
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01913.
    >> Share

  17. SCHULTALBERS M, Grote-Koska D, Cornberg M, Schmidt JJ, et al
    Plasma and ascites pharmacokinetic of meropenem in patients with decompensated liver cirrhosis and spontaneous bacterial peritonitis.
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01914.
    >> Share

  18. BRISSOT P, Loreal O
    Hemochromatoses.
    J Hepatol. 2021 Jul 11. pii: S0168-8278(21)00226.
    >> Share

  19. BRUIX J, Chan SL, Galle PR, Rimassa L, et al
    Systemic treatment of hepatocellular carcinoma. An EASL position paper.
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01903.
    >> Share

  20. VAQUERO J, Keitel V
    Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
    J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.
    >> Share

  21. CLARIA J, Curto A, Moreau R, Colsch B, et al
    Untargeted lipidomics uncovers lipid signatures distinguishing severe versus moderate forms of acutely decompensated cirrhosis.
    J Hepatol. 2021 Jul 7. pii: S0168-8278(21)01895.
    >> Share

  22. ZHU C, Boucheron N, Muller AC, Majek P, et al
    24-NorUrsodeoxycholic acid reshapes immunometabolism in CD8(+) T-cells and alleviates hepatic inflammation.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01886.
    >> Share

  23. SLADKY VC, Eichin F, Reiberger T, Villunger A, et al
    Polyploidy control in hepatic health and disease.
    J Hepatol. 2021 Jul 3. pii: S0168-8278(21)01879.
    >> Share

  24. ALVARADO-TAPIAS E, Vilades D, Brujats A, Villanueva C, et al
    Reply letter to correspondence entitled: "Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?"
    J Hepatol. 2021 Jul 2. pii: S0168-8278(21)01846.
    >> Share

  25. VAN DER MERWE S, Chokshi S, Bernsmeier C, Albillos A, et al
    The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S82-S100.
    >> Share

  26. TREBICKA J, Macnaughtan J, Schnabl B, Shawcross DL, et al
    The microbiota in cirrhosis and its role in hepatic decompensation.
    J Hepatol. 2021;75 Suppl 1:S67-S81.
    >> Share

  27. ENGELMANN C, Claria J, Szabo G, Bosch J, et al
    Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.
    J Hepatol. 2021;75 Suppl 1:S49-S66.
    >> Share

  28. JEPSEN P, Younossi ZM
    The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs.
    J Hepatol. 2021;75 Suppl 1:S3-S13.
    >> Share

  29. TANDON P, Montano-Loza AJ, Lai JC, Dasarathy S, et al
    Sarcopenia and frailty in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S147-S162.
    >> Share

  30. JALAN R, D'Amico G, Trebicka J, Moreau R, et al
    New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S14-S26.
    >> Share

  31. GARCIA-PAGAN JC, Francoz C, Montagnese S, Senzolo M, et al
    Management of the major complications of cirrhosis: Beyond guidelines.
    J Hepatol. 2021;75 Suppl 1:S135-S146.
    >> Share

  32. CARACENI P, Abraldes JG, Gines P, Newsome PN, et al
    The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.
    J Hepatol. 2021;75 Suppl 1:S118-S134.
    >> Share

  33. FERNANDEZ J, Piano S, Bartoletti M, Wey EQ, et al
    Management of bacterial and fungal infections in cirrhosis: The MDRO challenge.
    J Hepatol. 2021;75 Suppl 1:S101-S117.
    >> Share

  34. JALAN R, Szabo G
    New concepts and perspectives in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S1-S2.
    >> Share

    June 2021
  35. MA L, Wang L, Khatib SA, Chang CW, et al
    Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 30. pii: S0168-8278(21)01848.
    >> Share

  36. VITHAYATHIL M, Bridegwater J, Khan SA
    Medical therapies for intra-hepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 29. pii: S0168-8278(21)00238.
    >> Share

  37. QUITT O, Luo S, Meyer M, Xie Z, et al
    T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00443.
    >> Share

  38. D'AMICO G, Bernardi M, Angeli P
    TOWARDS A NEW DEFINITION OF DECOMPENSATED CIRRHOSIS.
    J Hepatol. 2021 Jun 19. pii: S0168-8278(21)00438.
    >> Share

  39. BOU SALEH M, Louvet A, Ntandja-Wandji LC, Boleslawski E, et al
    Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis.
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00416.
    >> Share

  40. GEIDL-FLUECK B, Gerber PA
    Reply to Comments on "Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00418.
    >> Share

  41. SELLAU J, Groneberg M, Hoenow S, Lotter H, et al
    The underlying cellular immune pathology of Entamoeba histolytica-induced hepatic amoebiasis.
    J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00221.
    >> Share

  42. WU J, Li H, Xu Z, Ran L, et al
    Population-specific cut-off points of fatty liver index for the diagnosis of hepatic steatosis.
    J Hepatol. 2021 Jun 9. pii: S0168-8278(21)00413.
    >> Share

    May 2021
  43. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
    Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
    >> Share

  44. BAUMERT TF
    "We can and should do better" - an interview with the 2020 Nobel prize laureates who revolutionized hepatology.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00312.
    >> Share

  45. CORNBERG M, Eberhardt CS
    Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00342.
    >> Share

  46. WANG H, Wen B, Chen J
    "Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?" -Reply.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00335.
    >> Share

  47. NAN Y, An J, Bao J, Chen H, et al
    The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00332.
    >> Share

  48. ZHOU HC, Liu CX, Pan WD, Shang LR, et al
    Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma.
    J Hepatol. 2021 May 15. pii: S0168-8278(21)00331.
    >> Share

  49. PINYOL R, Torrecilla S, Wang H, Montironi C, et al
    Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
    J Hepatol. 2021 May 13. pii: S0168-8278(21)00326.
    >> Share

  50. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Erratum to: "Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia" (J Hepatol 2021; 74: 428-441).
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00330.
    >> Share

  51. KUDO M, Matilla A, Santoro A, Melero I, et al
    CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00313.
    >> Share

  52. ROMBAUT M, Boeckmans J, Rodrigues RM, van Grunsven LA, et al
    Direct reprogramming of somatic cells into induced hepatocytes: cracking the Enigma code.
    J Hepatol. 2021 May 11. pii: S0168-8278(21)00314.
    >> Share

  53. YEO YH, Hwang J, Jeong D, Dang N, et al
    Surveillance of patients with cirrhosis remains suboptimal in the United States.
    J Hepatol. 2021 May 6. pii: S0168-8278(21)00307.
    >> Share

  54. HYUN J, Al Abo M, Dutta RK, Oh SH, et al
    Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
    J Hepatol. 2021 May 5. pii: S0168-8278(21)00298.
    >> Share

  55. CABRE N, Luciano-Mateo F, Chapski DJ, Baiges-Gaya G, et al
    Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression.
    J Hepatol. 2021 May 4. pii: S0168-8278(21)00302.
    >> Share

    April 2021
  56. IZZY M, Lin G, Watt KD
    Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?
    J Hepatol. 2021 Apr 28. pii: S0168-8278(21)00260.
    >> Share

  57. SENZOLO M, Garcia-Tsao G, Garcia-Pagan JC
    Current knowledge and management of portal vein thrombosis in cirrhosis.
    J Hepatol. 2021 Apr 27. pii: S0168-8278(21)00265.
    >> Share

  58. BETTINGER D, Kloeckner R, Boettler T, Thimme R, et al
    Reply: Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
    J Hepatol. 2021 Apr 26. pii: S0168-8278(21)00264.
    >> Share

  59. VILLANUEVA C, Albillos A, Genesca J, Garcia-Pagan JC, et al
    Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.
    J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00257.
    >> Share

  60. GINES P
    Robert W Schrier, an influential observer from outside Hepatology (1936-2021).
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00180.
    >> Share

  61. TAPPER EB, Nikirk S, Parikh N, Zhao L, et al
    Falls are common, morbid, and predictable in patients with cirrhosis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00247.
    >> Share

  62. OOI GJ, Meikle PJ, Huynh K, Earnest A, et al
    Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00248.
    >> Share

  63. GOLSE N, Vibert E, Vignon-Clementel IE
    Comments on: "A step forward to predict the risk of post-hepatectomy portal hypertension".
    J Hepatol. 2021 Apr 15. pii: S0168-8278(21)00242.
    >> Share

  64. SUNDARAM V
    Characterizing bacterial infections in acute-on-chronic liver failure among patients with cirrhosis from nonalcoholic steatohepatitis.
    J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00240.
    >> Share

  65. CRAMER T, Vaupel P
    Is tissue hypoxia the principle mechanism for immune evasion and malignant progression in Hepatocellular Carcinoma?
    J Hepatol. 2021 Apr 8. pii: S0168-8278(21)00228.
    >> Share

  66. PRINZ P
    Comments on "fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
    J Hepatol. 2021 Apr 5. pii: S0168-8278(21)00225.
    >> Share

    March 2021
  67. POCH T, Krause J, Casar C, Liwinski T, et al
    Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00219.
    >> Share

  68. MONTAGNESE S, Lauridsen M, Vilstrup H, Zarantonello L, et al
    A pilot study of Golexanolone, a new GABA-A receptor modulating steroid antagonist, in patients with covert hepatic encephalopathy.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00184.
    >> Share

  69. BASHO K, Bettinger D, Boettler T
    Reply to "IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?"
    J Hepatol. 2021 Mar 23. pii: S0168-8278(21)00187.
    >> Share

  70. POSE E, Torrents A, Reverter E, Perez-Campuzano V, et al
    A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00175.
    >> Share

  71. HARRISON SA, Gawrieh S, Roberts K, Lisanti CJ, et al
    Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00176.
    >> Share

  72. AN YA, Chen S, Deng Y, Wang ZV, et al
    The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00174.
    >> Share

  73. PUTERA M, Teh KB, Kumar R, Wong YJ, et al
    Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?
    J Hepatol. 2021 Mar 11. pii: S0168-8278(21)00167.
    >> Share

  74. STOCKHOFF L, Schneider H, Tergast TL, Cornberg M, et al
    Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
    J Hepatol. 2021 Mar 11. pii: S0168-8278(21)00168.
    >> Share

  75. LIAO SH, Chen CL, Hsu CY, Chien KL, et al
    Long-term Effectiveness of Population-wide Multifaceted Interventions for Hepatocellular Carcinoma in Taiwan.
    J Hepatol. 2021 Mar 6. pii: S0168-8278(21)00163.
    >> Share

  76. GEIDL-FLUECK B, Hochuli M, Nemeth A, Eberl A, et al
    Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial.
    J Hepatol. 2021 Mar 5. pii: S0168-8278(21)00161.
    >> Share

  77. ANSTEE QM, Darlay R, Cockell S, Meroni M, et al
    Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort" (J Hepatol [2020] 505-515).
    J Hepatol. 2021 Mar 4. pii: S0168-8278(21)00103.
    >> Share

  78. JAMIALAHMADI O, Bianco C, Pelusi S, Romeo S, et al
    Population attributable risk of cirrhosis and hepatocellular carcinoma due to genetic predisposition to fatty liver disease.
    J Hepatol. 2021 Mar 4. pii: S0168-8278(21)00164.
    >> Share

  79. WANG J, Liu D, Qi X
    A step forward to predict the risk of post-hepatectomy portal hypertension.
    J Hepatol. 2021 Mar 2. pii: S0168-8278(21)00159.
    >> Share

  80. MEIJNIKMAN AS, Bruin S, Groen AK, Nieuwdorp M, et al
    Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD.
    J Hepatol. 2021;74:748-749.
    >> Share

  81. MARJOT T, Moon AM, Cook JA, Abd-Elsalam S, et al
    Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
    J Hepatol. 2021;74:567-577.
    >> Share

  82. LUJAMBIO A, Maina F
    Turning up our understanding of liver cancer by a notch.
    J Hepatol. 2021;74:502-504.
    >> Share

    February 2021
  83. KEIDING S, Frisch K, Hofmann AF
    Reply to: "Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion".
    J Hepatol. 2021 Feb 20. pii: S0168-8278(21)00114.
    >> Share

  84. MALLET V
    Intravenous ketamine and progressive cholangiopathy in Covid-19 patients.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00107.
    >> Share

  85. HE Y, Feng D, Hwang S, Mackowiak B, et al
    Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IkappaBzeta target genes in hepatocytes.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00104.
    >> Share

  86. BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
    PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.
    >> Share

  87. FABRIS L, Cadamuro M, Fouassier L
    Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche.
    J Hepatol. 2021 Feb 11. pii: S0168-8278(20)33892.
    >> Share

  88. HARRISON SA, Bashir MR, Lee KJ, Shim-Lopez J, et al
    A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    J Hepatol. 2021 Feb 10. pii: S0168-8278(21)00099.
    >> Share

  89. LIANG B, Zhou Y, Qian M, Xu M, et al
    TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00095.
    >> Share

  90. LIEBE R, Esposito I, Bock HH, Dahl SV, et al
    Diagnosis and management of secondary causes of steatohepatitis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00096.
    >> Share

  91. CORNBERG M, Buti M, Eberhardt CS, Grossi PA, et al
    EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
    J Hepatol. 2021 Feb 6. pii: S0168-8278(21)00081.
    >> Share

  92. TERGAST TL, Schultalbers M, Wedemeyer H, Cornberg M, et al
    IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?
    J Hepatol. 2021 Feb 3. pii: S0168-8278(21)00089.
    >> Share

  93. GUPTA P, Soundararajan R, Patel A, Kumar-M P, et al
    Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis.
    J Hepatol. 2021 Feb 3. pii: S0168-8278(21)00091.
    >> Share

  94. BEAUFRERE A, Calderaro J, Paradis V
    Combined hepatocellular-cholangiocarcinoma: An update.
    J Hepatol. 2021 Feb 2. pii: S0168-8278(21)00084.
    >> Share

  95. MUSHTAQ K, Khan MU, Iqbal F, Alsoub DH, et al
    NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues.
    J Hepatol. 2021;74:482-484.
    >> Share

  96. JI D, Cheng G, Lau G
    Reply to: "NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues".
    J Hepatol. 2021;74:484-485.
    >> Share

  97. RIPOLL C, Zipprich A
    Open or closed window: That is the question.
    J Hepatol. 2021;74:485-486.
    >> Share

  98. ANAND A, Kumar R, Shalimar
    PREDICTing acute-on-chronic liver failure in patients with acute decompensation.
    J Hepatol. 2021;74:478-479.
    >> Share

  99. HERNAEZ R, Kanwal F
    Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure".
    J Hepatol. 2021;74:477.
    >> Share

  100. GOUDSMIT BFJ, Tushuizen ME, Putter H, Braat AE, et al
    The role of the model for end-stage liver disease-sodium score and joint models for 90-day mortality prediction in patients with acute-on-chronic liver failure.
    J Hepatol. 2021;74:475-476.
    >> Share

    January 2021
  101. SONG Q, Wang J, Griffiths A, Song Z, et al
    Reply to: "NNMT aggravates hepatic steatosis but alleviates liver injury in alcoholic liver disease" and "Two sides of NNMT in alcoholic and nonalcoholic fatty liver development".
    J Hepatol. 2021 Jan 30. pii: S0168-8278(21)00083.
    >> Share

  102. GWAG T, Meng Z, Sui Y, Helsley RN, et al
    Erratum to: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis [J Hepatol (2019); 70 (5): 930-940].
    J Hepatol. 2021 Jan 29. pii: S0168-8278(21)00003.
    >> Share

  103. WU X, Poulsen KL, Sanz-Garcia C, Huang E, et al
    Erratum to: "MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcoholic-associated fatty liver and steatohepatitis (J Hepatol 2020; 73: 616-627)".
    J Hepatol. 2021 Jan 29. pii: S0168-8278(21)00014.
    >> Share

  104. JAVITT NB
    Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion.
    J Hepatol. 2021 Jan 25. pii: S0168-8278(21)00044.
    >> Share

  105. SAMUEL D
    Systemic inflammation and liver cirrhosis complications: driving or secondary event? How to square the circle?
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00001.
    >> Share

  106. LONG J, Bian J, Zhao H
    Polygenic risk score: a promising predictor for hepatocellular carcinoma in the population with nonalcoholic fatty liver disease.
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00019.
    >> Share

  107. JEPSEN P, West J
    We need stronger evidence for (or against) hepatocellular carcinoma surveillance.
    J Hepatol. 2021 Jan 16. pii: S0168-8278(21)00020.
    >> Share

  108. GOLDBERG D, Mantero A, Newcomb C, Delgado C, et al
    Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score.
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00004.
    >> Share

  109. FAN R, Yin X, Hou J
    Reply to "External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs".
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00011.
    >> Share

  110. BURTON AR, Pallett LJ
    IL-2 leaves its mark in cirrhosis.
    J Hepatol. 2021 Jan 6. pii: S0168-8278(20)33833.
    >> Share

  111. FORLANO R, Mullish BH, Maurice JB, Thursz MR, et al
    NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials.
    J Hepatol. 2021;74:241-242.
    >> Share

  112. WU Y, Kumar R, Huang J, Wang M, et al
    FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD).
    J Hepatol. 2021;74:247-248.
    >> Share

  113. NAYAGAM JS, Strautnieks S, Joshi D, Thompson RJ, et al
    Challenges in understanding the consequences of variants in ABCB4 gene.
    J Hepatol. 2021;74:242-243.
    >> Share

  114. TSOCHATZIS EA, Srivastava A, Rosenberg W
    Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)".
    J Hepatol. 2021;74:248-249.
    >> Share

  115. SAVALE L, Sitbon O
    Reply to: "Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?"
    J Hepatol. 2021;74:238-239.
    >> Share

  116. KOLHE K, Tripathi DM, Kaur S
    Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?
    J Hepatol. 2021;74:237-238.
    >> Share

  117. STATTERMAYER AF, Ferenci P, Trauner M
    Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene".
    J Hepatol. 2021;74:244-245.
    >> Share

    December 2020
  118. FERRUSQUIA-ACOSTA J, Turco L, Hernandez-Gea V
    Reply to: "Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications".
    J Hepatol. 2020 Dec 29. pii: S0168-8278(20)33837.
    >> Share

  119. SHARMA S, Anand A, Saraya A
    Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications.
    J Hepatol. 2020 Dec 22. pii: S0168-8278(20)33736.
    >> Share

  120. WANG H, Chen J
    Reply to: "Prospective validation of Baveno VI criteria in virally supressed HBV cirrhosis - more evidence is needed".
    J Hepatol. 2020 Dec 19. pii: S0168-8278(20)33839.
    >> Share

  121. SHARMA S, Agarwal S
    Prospective validation of Baveno VI criteria in virally supressed HBV cirrhosis - more evidence is needed.
    J Hepatol. 2020 Dec 19. pii: S0168-8278(20)33687.
    >> Share

  122. LISMAN T, Luyendyk JP
    Response to "The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis".
    J Hepatol. 2020 Dec 18. pii: S0168-8278(20)33890.
    >> Share

  123. CALVARUSO V, Craxi A
    Reply to letters to the Editor on manuscript "Hepatic benefits of HCV cure". JHEPAT-D-20-01349R1.
    J Hepatol. 2020 Dec 17. pii: S0168-8278(20)33888.
    >> Share

  124. SARKAR M, Grab J, Irani RA
    Reply to: "Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?"
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33806.
    >> Share

  125. NINGARHARI M, Caruso S, Hirsch TZ, Bayard Q, et al
    Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33846.
    >> Share

  126. AVANCENA ALV, Miller N, Uttal SE, Hutton DW, et al
    Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.
    J Hepatol. 2020 Dec 13. pii: S0168-8278(20)33841.
    >> Share

  127. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884].
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33773.
    >> Share

  128. PHILLIPS J, Senaratne S
    Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33694.
    >> Share

  129. BRESSON-HADNI S, Montange D, Richou C, Brumpt E, et al
    Tobacco, cannabis, and liquorice: Hidden players altering albendazole metabolism in patients with hepatic alveolar echinococcosis.
    J Hepatol. 2020 Dec 10. pii: S0168-8278(20)33749.
    >> Share

  130. ARROYO V, Angeli P, Moreau R, Jalan R, et al
    The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis.
    J Hepatol. 2020 Dec 7. pii: S0168-8278(20)33836.
    >> Share

  131. BOYER-DIAZ Z, Aristu-Zabalza P, Andres-Rozas M, Robert C, et al
    Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33832.
    >> Share

  132. TREBICKA J, Fernandez J, Arroyo V
    Reply to: Correspondence on 'The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology'.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33765.
    >> Share

  133. WEIL D, Thevenot T, Saas P, Di Martino V, et al
    Relevance of platelet-derived microvesicles in cirrhosis: The debate remains open.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33745.
    >> Share

  134. BAUMERT TF
    The Nobel Prize in Medicine 2020 for the Discovery of Hepatitis C Virus: Transforming Hepatology.
    J Hepatol. 2020;73:1303-1305.
    >> Share

  135. VASAVAN T, Deepak S, Jayawardane IA, Lucchini M, et al
    Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33825.
    >> Share

  136. DIGGS LP, Ruf B, Ma C, Heinrich B, et al
    CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33824.
    >> Share

  137. MARTINEZ-CHANTAR ML, Foti M
    NFATc4: New hub in NASH development.
    J Hepatol. 2020;73:1313-1315.
    >> Share

  138. TANWAR S, Srivastava A, Rosenberg W
    Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:1580-1581.
    >> Share

  139. HERNAEZ R, Liu Y, Kanwal F
    Reply to: "Model for end-stage liver disease-sodium in acute-on-chronic liver failure".
    J Hepatol. 2020;73:1579-1580.
    >> Share

  140. MOSCA A, Panera N, Maggiore G, Alisi A, et al
    From pregnant women to infants: Non-alcoholic fatty liver disease is a poor inheritance.
    J Hepatol. 2020;73:1590-1592.
    >> Share

  141. GOH BKP
    Letter regarding "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2020;73:1576.
    >> Share

  142. HOBEIKA C, Fuks D
    Reply to: 'Letter regarding "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers"'.
    J Hepatol. 2020;73:1577-1578.
    >> Share

  143. VALI Y, Anstee QM, Bossuyt PM
    Reply to: "Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:1582-1583.
    >> Share

  144. MAK LY, Yuen MF, Seto WK
    Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement".
    J Hepatol. 2020;73:1573-1574.
    >> Share

  145. MANKA P, Canbay A, Bechmann LP
    Model for end-stage liver disease-sodium in acute-on-chronic liver failure.
    J Hepatol. 2020;73:1578-1579.
    >> Share

  146. ESLAM M, George J
    Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.
    J Hepatol. 2020;73:1575.
    >> Share

  147. RATZIU V, Rinella M, Beuers U, Loomba R, et al
    The times they are a-changin' (for NAFLD as well).
    J Hepatol. 2020;73:1307-1309.
    >> Share

  148. JALAN R, Arroyo V
    Organ allocation for patients with acute-on-chronic liver failure: Time to look beyond MELD-sodium?
    J Hepatol. 2020;73:1316-1318.
    >> Share

    November 2020
  149. KUPRIYANOVA Y, Zaharia OP, Bobrov P, Karusheva Y, et al
    Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus.
    J Hepatol. 2020 Nov 28. pii: S0168-8278(20)33817.
    >> Share

  150. BIANCO C, Jamialahmadi O, Pelusi S, Baselli G, et al
    Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
    J Hepatol. 2020 Nov 25. pii: S0168-8278(20)33811.
    >> Share

  151. SU F, Weiss NS, Beste LA, Moon AM, et al
    Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B.
    J Hepatol. 2020 Nov 24. pii: S0168-8278(20)33807.
    >> Share

  152. DING Q, Ma Y, Lai S, Dou X, et al
    NNMT aggravates hepatic steatosis, but alleviates liver injury in alcoholic liver disease.
    J Hepatol. 2020 Nov 24. pii: S0168-8278(20)33812.
    >> Share

  153. KELLUM JA, Nadim MK
    Acute kidney disease and cirrhosis.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33756.
    >> Share

  154. KRASSENBURG LAP, Maan R, Ramji A, Manns MP, et al
    Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33805.
    >> Share

  155. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
    PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.
    J Hepatol. 2020 Nov 20. pii: S0168-8278(20)33772.
    >> Share

  156. CHEN H, Cai J, Wang J, Qiu Y, et al
    Targeting Nestin(+) hepatic stellate cells ameliorates liver fibrosis by facilitating TbetaRI degradation.
    J Hepatol. 2020 Nov 17. pii: S0168-8278(20)33769.
    >> Share

  157. HUANG YH, Zhang CZ, Huang QS, Yeong J, et al
    Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33763.
    >> Share

  158. GOLSE N, Joly F, Combari P, Lewin M, et al
    Predicting the risk of post-hepatectomy portal hypertension using a digital twin: a clinical proof of concept.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33761.
    >> Share

  159. ARECHEDERRA M, Bazai SK, Abdouni A, Sequera C, et al
    ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.
    J Hepatol. 2020 Nov 13. pii: S0168-8278(20)33758.
    >> Share

  160. MEHTA N, Dodge JL, Roberts JP, Yao FY, et al
    A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33750.
    >> Share

  161. KUCUKOGLU O, Sowa JP, Mazzolini GD, Syn WK, et al
    Hepatokines and adipokines in NASH-related hepatocellular carcinoma.
    J Hepatol. 2020 Nov 5. pii: S0168-8278(20)33746.
    >> Share

  162. ZANETTO A, Simioni P, Russo FP
    Hepatic benefits of HCV cure: don't forget coagulation!
    J Hepatol. 2020 Nov 5. pii: S0168-8278(20)33747.
    >> Share

  163. ANTOINE DJ, Jenkins RE, Dear JW, Williams DP, et al
    Retraction notice to "Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity": J Hepatol 56(2012)1070-1079.
    J Hepatol. 2020;73:1297.
    >> Share

  164. JOTHIMANI D, Venugopal R, Abedin MF, Kaliamoorthy I, et al
    COVID-19 and the liver.
    J Hepatol. 2020;73:1231-1240.
    >> Share

  165. MEHTANI R, Roy A, Verma N, Premkumar M, et al
    Beta-blockers in refractory ascites - is it truly the end of the road?
    J Hepatol. 2020;73:1290-1291.
    >> Share

  166. TELLEZ L, Ibanez-Samaniego L, Banares R, Albillos A, et al
    Reply to: "Beta-blockers in refractory ascites - is it truly the end of the road?"
    J Hepatol. 2020;73:1291-1292.
    >> Share

  167. UNFRIED JP, Fortes P
    SMIM30, a tiny protein with a big role in liver cancer.
    J Hepatol. 2020;73:1010-1012.
    >> Share

  168. HUANG J, Kumar R, Wang M, Zhu Y, et al
    MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant?
    J Hepatol. 2020;73:1265-1267.
    >> Share

  169. ESLAM M, George J
    Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice.
    J Hepatol. 2020;73:1268-1269.
    >> Share

  170. VAN HEES S, Muyindike W, Erem G, Ocama P, et al
    Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda.
    J Hepatol. 2020;73:1271-1273.
    >> Share

  171. SINGAL AG, Lampertico P, Nahon P
    Reply to: "Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda".
    J Hepatol. 2020;73:1273-1274.
    >> Share

    October 2020
  172. WANG J, Wang Y, Chu Y, Li Z, et al
    Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma.
    J Hepatol. 2020 Oct 30. pii: S0168-8278(20)33739.
    >> Share

  173. CHAN SL
    Hyperprogression in hepatocellular carcinoma: Illusion or reality?
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33669.
    >> Share

  174. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33690.
    >> Share

  175. MOHS A, Otto T, Schneider KM, Peltzer M, et al
    Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33695.
    >> Share

  176. BASHO K, Zoldan K, Schultheiss M, Bettinger D, et al
    IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33692.
    >> Share

  177. SHIHA G, Mikhail N, Soliman R
    External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33688.
    >> Share

  178. DEPAIRE M, Larrue H, Rudler M, Nault JC, et al
    Futility criteria for preemptive TIPS in patients with cirrhosis and variceal bleeding are still missing in most severe patients!
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33689.
    >> Share

  179. MOGA L, Laroyenne A, Larrue H, Bureau C, et al
    Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33691.
    >> Share

  180. ROSE CF, Amodio P, Bajaj JS, Dhiman RK, et al
    Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy.
    J Hepatol. 2020 Oct 21. pii: S0168-8278(20)30466.
    >> Share

  181. FERRUSQUIA-ACOSTA J, Bassegoda O, Turco L, Reverter E, et al
    Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33683.
    >> Share

  182. CARBONE M, Ronca V, Invernizzi P
    Reply to: "A spotlight on natural killer cells in primary biliary cholangitis".
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33663.
    >> Share

  183. HYDES T, Khakoo SI
    A spotlight on natural killer cells in primary biliary cholangitis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33595.
    >> Share

  184. CAI SY, Yu D, Soroka CJ, Wang J, et al
    Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33680.
    >> Share

  185. WANG H, Wen B, Chang X, Wu Q, et al
    Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33678.
    >> Share

  186. MORIKAWA R, Nakamoto N, Amiya T, Chu PS, et al
    Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33677.
    >> Share

  187. FRENETTE C, Kayali Z, Mena E, Mantry PS, et al
    Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33673.
    >> Share

  188. ZHU C, Ho YJ, Salomao MA, Dapito DH, et al
    Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33676.
    >> Share

  189. KIM TH, Koh YH, Kim BH, Kim MJ, et al
    Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase trial.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33670.
    >> Share

  190. LIU C, Zha Z, Zhou C, Chen Y, et al
    Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33674.
    >> Share

  191. FONDEVILA MF, Mercado-Gomez M, Rodriguez A, Gonzalez-Rellan MJ, et al
    Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33671.
    >> Share

  192. MAGAZ M, Alvarez-Larran A, Colomer D, Lopez M, et al
    Reply to: Correspondence on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis".
    J Hepatol. 2020 Oct 2. pii: S0168-8278(20)33621.
    >> Share

  193. WANG Y, Lu F, Zhao J
    Reply to: Correspondence relating to "SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19".
    J Hepatol. 2020;73:996-998.
    >> Share

  194. MEHAL WZ
    From mice to humans: Unravelling the genetic levers of NASH.
    J Hepatol. 2020;73:749-751.
    >> Share

  195. O'BRIEN A, Karvellas CJ
    Acute-on-chronic liver failure: The challenge of PREDICTing who and when.
    J Hepatol. 2020;73:755-756.
    >> Share

  196. HUO TI, Ho SY, Ko CC
    Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers.
    J Hepatol. 2020;73:972-973.
    >> Share

  197. SCHWARZKOPF KM, Eberle L, Uschner FE, Klein S, et al
    Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?
    J Hepatol. 2020;73:980-982.
    >> Share

  198. TREBICKA J, Gu W, Garcia-Pagan JC, Bosch J, et al
    Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?": pTIPS for variceal bleeding in ACLF patients: when and why?
    J Hepatol. 2020;73:977-979.
    >> Share

  199. XIANG X, Hwang S, Gao B
    Reply to: "Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?": The search for an optimal mouse model.
    J Hepatol. 2020;73:982-984.
    >> Share

  200. ELHENCE A, Kumar R, Shalimar
    Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?
    J Hepatol. 2020;73:976-977.
    >> Share

  201. KIM N, Seong J
    Reply to: "Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers".
    J Hepatol. 2020;73:973-974.
    >> Share

    September 2020
  202. WEN Z, Feng Y, Yan X
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Sep 29. pii: S0168-8278(20)30491.
    >> Share

  203. GRONBAEK H, Gantzel RH, Laursen TL, Kazankov K, et al
    Macrophage markers and innate immunity in cirrhosis.
    J Hepatol. 2020 Sep 26. pii: S0168-8278(20)30486.
    >> Share

  204. PAPATHEODORIDIS G, Sypsa V, Lampertico P
    Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
    J Hepatol. 2020 Sep 25. pii: S0168-8278(20)33615.
    >> Share

  205. SCHUMACHER N, Yan K, Gandrass M, Muller M, et al
    Cell-autonomous hepatocyte-specific GP130 signalling is sufficient to trigger a robust innate immune response in mice.
    J Hepatol. 2020 Sep 25. pii: S0168-8278(20)33664.
    >> Share

  206. TREMBLAY D, Mascarenhas J, Schiano T, Naymagon L, et al
    Comment on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis".
    J Hepatol. 2020 Sep 24. pii: S0168-8278(20)30531.
    >> Share

  207. ZHENG KI, Liu C, Li J, Zhao L, et al
    Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis.
    J Hepatol. 2020 Sep 21. pii: S0168-8278(20)30447.
    >> Share

  208. ARGIRION I, Mahale P, Pfeiffer RM, Koshiol J, et al
    Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma.
    J Hepatol. 2020 Sep 19. pii: S0168-8278(20)30465.
    >> Share

  209. PARISINOS CA, Wilman HR, Thomas EL, Kelly M, et al
    Corrigendum to: "Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis" [J Hepatol (2020) 241-251].
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33603.
    >> Share

  210. SECKLER F, Doussot A, Colpart P, Turco C, et al
    Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift?
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)30366.
    >> Share

  211. SCHATTENBERG JM, Straub BK
    On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis.
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)30475.
    >> Share

  212. ALFAIATE D, Clement S, Goossens N, Negro F, et al
    Reply to: "Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma".
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)30543.
    >> Share

  213. KIM N, Cheng J, Jung I, Liang J, et al
    Corrigendum to: "Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma" [J Hepatol (2020) 121-129].
    J Hepatol. 2020 Sep 10. pii: S0168-8278(20)33602.
    >> Share

  214. TONON M, Rosi S, Gambino CG, Piano S, et al
    Natural history of acute kidney disease in patients with cirrhosis.
    J Hepatol. 2020 Sep 9. pii: S0168-8278(20)33612.
    >> Share

  215. CHAN LK, Wai-Hung Ho D, Kam CS, Yung-Tuen Chiu E, et al
    RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma.
    J Hepatol. 2020 Sep 9. pii: S0168-8278(20)33610.
    >> Share

  216. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Corrigendum to: "Portopulmonary hypertension in the current era of pulmonary hypertension management" [J Hepatol (2020);73:130-139].
    J Hepatol. 2020 Sep 7. pii: S0168-8278(20)33591.
    >> Share

  217. FABRIS L, Andersen JB, Fouassier L
    Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment.
    J Hepatol. 2020 Sep 5. pii: S0168-8278(20)30471.
    >> Share

  218. MERLI M
    Nutrition in cirrhosis: Dos and Don'ts.
    J Hepatol. 2020 Sep 2. pii: S0168-8278(20)30474.
    >> Share

  219. SERPER M, Shaked A, Olthoff KM, Hoteit M, et al
    A local response to COVID-19 for advanced liver disease: Current model of care, challenges and opportunities.
    J Hepatol. 2020;73:708-709.
    >> Share

  220. VALENTI L, Jamialahmadi O, Romeo S
    Lack of genetic evidence that fatty liver disease predisposes to COVID-19.
    J Hepatol. 2020;73:709-711.
    >> Share

  221. DI GIORGIO A, Nicastro E, Speziani C, De Giorgio M, et al
    Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy.
    J Hepatol. 2020;73:702-705.
    >> Share

  222. JI D, Xu J, Qin E, Zhang D, et al
    Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'.
    J Hepatol. 2020;73:718-719.
    >> Share

  223. BIQUARD L, Valla D, Rautou PE
    No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.
    J Hepatol. 2020;73:717-718.
    >> Share

  224. RICKE J, Sangro B, Malfertheiner P, Seidensticker M, et al
    Reply to: "Toxicity and dosimetry in SORAMIC study".
    J Hepatol. 2020;73:735-736.
    >> Share

  225. REINDERS M, Braat A, Lam M
    Toxicity and dosimetry in SORAMIC study.
    J Hepatol. 2020;73:734-735.
    >> Share

  226. DYSON JK, Jones DEJ
    UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.
    J Hepatol. 2020;73:499-501.
    >> Share

  227. PAISANT A, Vilgrain V, Aube C
    Reply to: "Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents".
    J Hepatol. 2020;73:716-717.
    >> Share

  228. CHOI SH, Kim SY, Lim YS
    Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents.
    J Hepatol. 2020;73:714-715.
    >> Share

  229. ILIC I, Milovanovic T
    The risk-benefit assessment of liver biopsy in times of non-invasive screening for liver fibrosis.
    J Hepatol. 2020;73:701-702.
    >> Share

  230. GUIU B
    Stereotactic body radiation therapy vs. radiofrequency ablation in HCC: comparing noncomparable data.
    J Hepatol. 2020;73:727-728.
    >> Share

  231. JI D, Zhang D, Lau G
    Reply to: 'NAFLD or comorbidities, that is the question'.
    J Hepatol. 2020;73:724-725.
    >> Share

  232. PONZIANI FR, Gasbarrini A, Pompili M
    NAFLD or comorbidities, that is the question.
    J Hepatol. 2020;73:723.
    >> Share

    August 2020
  233. CHARETTE JH, Burak KW, Coffin CS, Congly SE, et al
    Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma.
    J Hepatol. 2020 Aug 31. pii: S0168-8278(20)30458.
    >> Share

  234. GENESCA J
    Reply to: "Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma".
    J Hepatol. 2020 Aug 24. pii: S0168-8278(20)30484.
    >> Share

  235. CARACENI P, Tufoni M, Zaccherini G, Riggio O, et al
    On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites.
    J Hepatol. 2020 Aug 24. pii: S0168-8278(20)33551.
    >> Share

  236. XU Z, Li H, Tian S, Wu J, et al
    Blood biomarkers for the diagnosis of hepatic steatosis in metabolic dysfunction-associated fatty liver disease.
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30371.
    >> Share

  237. SERENARI M, Ravaioli F, Cucchetti A, Kim SU, et al
    Reply to: "Response to A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30442.
    >> Share

  238. FAN L, Lai R, Ma N, Dong Y, et al
    miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30541.
    >> Share

  239. RHEE H, Cho ES, Nahm JH, Jang M, et al
    Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30544.
    >> Share

  240. KIM CG, Kim C, Yoon SE, Kim KH, et al
    Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    J Hepatol. 2020 Aug 15. pii: S0168-8278(20)30540.
    >> Share

  241. MANNING C, Alam SM
    Response to "A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Aug 14. pii: S0168-8278(20)30380.
    >> Share

  242. SOLA E, Pose E, Campion D, Piano S, et al
    ENDPOINTS AND DESIGN OF CLINICAL TRIALS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS: POSITION PAPER OF THE LIVERHOPE CONSORTIUM.
    J Hepatol. 2020 Aug 14. pii: S0168-8278(20)30536.
    >> Share

  243. CALVARUSO V, Craxi A
    Hepatic benefits of HCV cure.
    J Hepatol. 2020 Aug 7. pii: S0168-8278(20)30530.
    >> Share

  244. IAVARONE M, D'Ambrosio R, Lampertico P
    Authors' reply on HIGH RATES OF 30-DAY MORTALITY IN PATIENTS WITH CIRRHOSIS AND COVID-19.
    J Hepatol. 2020 Aug 6. pii: S0168-8278(20)30524.
    >> Share

  245. CALVARUSO V, Bruix J
    Towards personalized screening for hepatocellular carcinoma: still not there.
    J Hepatol. 2020 Aug 5. pii: S0168-8278(20)30405.
    >> Share

  246. GAUL S, Leszczynska A, Alegre F, Kaufmann B, et al
    Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.
    J Hepatol. 2020 Aug 4. pii: S0168-8278(20)30522.
    >> Share

  247. JI D, Qin E, Xu J, Zhang D, et al
    Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study.
    J Hepatol. 2020;73:451-453.
    >> Share

  248. MERAT SJ, Bru C, van de Berg D, Molenkamp R, et al
    Erratum to: 'Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance' (J Hepatol 2019; 71(1): 14-24).
    J Hepatol. 2020 Aug 1. pii: S0168-8278(20)30455.
    >> Share

  249. PRAKTIKNJO M, Torner J, Simon-Talero M, Gu W, et al
    Reply to: "Definition of SPSS: we need to speak the same language": Computer-assisted image processing for better quantification.
    J Hepatol. 2020;73:464-465.
    >> Share

  250. NICOARA-FARCAU O, Wang X, Luo X
    Definition of SPSS: we need to speak the same language.
    J Hepatol. 2020;73:463-464.
    >> Share

    July 2020
  251. KOMOLL RM, Hu Q, Olarewaju O, von Dohlen L, et al
    MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma.
    J Hepatol. 2020 Jul 30. pii: S0168-8278(20)30492.
    >> Share

  252. LUO YD, Fang L, Yu HQ, Zhang J, et al
    p53 haploinsufficiency and increased mTOR signaling define a subset of aggressive hepatocellular carcinoma.
    J Hepatol. 2020 Jul 29. pii: S0168-8278(20)30489.
    >> Share

  253. KJAERGAARD K, Frisch K, Sorensen M, Munk OL, et al
    Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30481.
    >> Share

  254. DU M, Wang X, Yuan L, Liu B, et al
    Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30482.
    >> Share

  255. SANGRO B, Melero I, Wadhawan S, Finn RS, et al
    Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
    J Hepatol. 2020 Jul 22. pii: S0168-8278(20)30479.
    >> Share

  256. FAN R, Papatheodoridis G, Sun J, Innes H, et al
    aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30478.
    >> Share

  257. LOHSE AW, Sebode M, Jorgensen MH, Ytting H, et al
    Second-line and Third-line therapy for Autoimmune Hepatitis A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30470.
    >> Share

  258. SERENARI M, Ravaioli F, Cucchetti A, Kim SU, et al
    Reply to: "Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Jul 20. pii: S0168-8278(20)30388.
    >> Share

  259. XU G, Xiao Y, Jin B, Sang X, et al
    Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma.
    J Hepatol. 2020 Jul 20. pii: S0168-8278(20)30343.
    >> Share

  260. TAJES SR, Pocurull A, Castillo J, Casanova G, et al
    Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions in the near future.
    J Hepatol. 2020 Jul 19. pii: S0168-8278(20)30472.
    >> Share

  261. SONG Y, An O, Ren X, Man Chan TH, et al
    RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis.
    J Hepatol. 2020 Jul 18. pii: S0168-8278(20)30476.
    >> Share

  262. ZHANG X, Fan L, Wu J, Xu H, et al
    Erratum to: "Macrophage p38 alpha promotes nutritional steatohepatitis through M1 polarization (J Hepatol 2019; 71(1):163-174)".
    J Hepatol. 2020 Jul 17. pii: S0168-8278(20)30390.
    >> Share

  263. VERNA EC, Akushevich L, Vainorius M, Fried MW, et al
    Reply to: "HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?"
    J Hepatol. 2020 Jul 15. pii: S0168-8278(20)30386.
    >> Share

  264. MAGAZ M, Alvarez-Larran A, Colomer D, Lopez-Guerra M, et al
    Next generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30456.
    >> Share

  265. SABOO K, Shamsaddini A, Iyer MV, Hu C, et al
    Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30457.
    >> Share

  266. MCPHAIL MJW, Coen M
    Metabolomics to discriminate between acute decompensation and acute-on-chronic liver failure in cirrhosis.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30183.
    >> Share

  267. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
    The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology (120/120).
    J Hepatol. 2020 Jul 10. pii: S0168-8278(20)30384.
    >> Share

  268. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17-25).
    J Hepatol. 2020 Jul 9. pii: S0168-8278(20)30389.
    >> Share

  269. MOREAU R, Aguilar F, Arroyo V
    Reply to: "Metabolomics to discriminate between acute decompensation and acute-on-chronic liver failure in cirrhosis".
    J Hepatol. 2020 Jul 8. pii: S0168-8278(20)30340.
    >> Share

  270. MEUNIER L, Pageaux GP, Coilly A
    HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?
    J Hepatol. 2020 Jul 8. pii: S0168-8278(20)30345.
    >> Share

  271. RINELLA ME, Noureddin M
    STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus.
    J Hepatol. 2020;73:9-11.
    >> Share

  272. LAZARUS JV, Cortez-Pinto H, Anstee QM
    Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:221-222.
    >> Share

  273. SHAH S, Dhami-Shah H, Kamble S, Shukla A, et al
    FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:216-217.
    >> Share

  274. LEUNG M, Piao C, Sarkar S
    NAFLD referral patterns in a large US academic center.
    J Hepatol. 2020;73:218-219.
    >> Share

  275. TSOCHATZIS EA, Srivastava A, Rosenberg W
    Reply to: "FIB-4 cut off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:217-218.
    >> Share

  276. MENDEZ-SANCHEZ N, Valencia-Rodriguez A
    Caveats for the implementation of global strategies against non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:220.
    >> Share

  277. ZOU ZY, Fan JG
    Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:214-216.
    >> Share

    June 2020
  278. AUDUREAU E, Carrat F, Layese R, Cagnot C, et al
    Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.
    J Hepatol. 2020 Jun 29. pii: S0168-8278(20)30394.
    >> Share

  279. DONG P, Wang X, Liu L, Tang W, et al
    Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
    J Hepatol. 2020 Jun 28. pii: S0168-8278(20)30400.
    >> Share

  280. RUART M, Chavarria L, Camprecios G, Suarez-Herrera N, et al
    Corrigendum to: "Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury" [J Hepatol (2019) 458-469].
    J Hepatol. 2020 Jun 27. pii: S0168-8278(20)30354.
    >> Share

  281. LAMPL S, Janas MK, Donakonda S, Brugger M, et al
    Reduced mitochondrial resilience enables non-canonical induction of apoptosis after TNF receptor signaling in virus-infected hepatocytes.
    J Hepatol. 2020 Jun 26. pii: S0168-8278(20)30398.
    >> Share

  282. HAMON A, Piquet-Pellorce C, Dimanche-Boitrel MT, Samson M, et al
    Intrahepatocytic necroptosis is dispensable for hepatocyte death in murine immune-mediated hepatitis.
    J Hepatol. 2020 Jun 23. pii: S0168-8278(20)30308.
    >> Share

  283. FRAGA M, Moradpour D, Artru F, Romailler E, et al
    Hepatocellular Type II Fibrinogen Inclusions in a Patient with Severe COVID-19 and Hepatitis.
    J Hepatol. 2020 Jun 22. pii: S0168-8278(20)30393.
    >> Share

  284. BASSEGODA O, Sola E, Gines P
    Reply to: "Transition of AKI to CKD in cirrhosis - effect of baseline eGFR and unanswered questions".
    J Hepatol. 2020 Jun 21. pii: S0168-8278(20)30287.
    >> Share

  285. GAO F, Huang ZM
    The impact of COVID-19 on the clinical outcome of patients with cirrhosis deserves more attention and research.
    J Hepatol. 2020 Jun 20. pii: S0168-8278(20)30397.
    >> Share

  286. MEDHAT MA, El Kassas M
    Letter regarding [High rates of 30-day mortality in patients with cirrhosis and COVID-19].
    J Hepatol. 2020 Jun 20. pii: S0168-8278(20)30396.
    >> Share

  287. KUMAR R, Kerbert AJC, Sheikh MF, Roth N, et al
    Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding.
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30381.
    >> Share

  288. BABU RO, Hang Lui VC, Chen Y, Wan Yiu RS, et al
    Beta-amyloid deposition around hepatic bile ducts is a novel pathobiological and diagnostic feature of biliary atresia.
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30383.
    >> Share

  289. COLNOT S, Lechel A
    Maternal obesity: A severe risk factor in hepatocarcinogenesis?
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30385.
    >> Share

  290. PAPATHEODORIDIS GV, Dalekos GN, Idilman R, Sypsa V, et al
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Jun 15. pii: S0168-8278(20)30382.
    >> Share

  291. SINGH I, De A, Singh V
    Transition of AKI to CKD in cirrhosis - effect of baseline eGFR and unanswered questions.
    J Hepatol. 2020 Jun 12. pii: S0168-8278(20)30184.
    >> Share

  292. RAI RP, Liu Y, Iyer SS, Liu S, et al
    Blocking integrin alpha4beta7-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis.
    J Hepatol. 2020 Jun 12. pii: S0168-8278(20)30375.
    >> Share

  293. LENS S, Baiges A, Alvarado E, LLop E, et al
    Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    J Hepatol. 2020 Jun 11. pii: S0168-8278(20)30368.
    >> Share

  294. IAVARONE M, D'Ambrosio R, Soria A, Triolo M, et al
    High rates of 30-day mortality in patients with cirrhosis and COVID-19.
    J Hepatol. 2020 Jun 8. pii: S0168-8278(20)30365.
    >> Share

  295. JEPSEN P, Kraglund F, West J, Villadsen GE, et al
    Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis.
    J Hepatol. 2020 Jun 5. pii: S0168-8278(20)30363.
    >> Share

  296. ZHANG M, Yang H, Wan L, Wang Z, et al
    Single cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Jun 4. pii: S0168-8278(20)30360.
    >> Share

  297. SHIHA G
    External validation of non-invasive predictors of hepatocellular carcinoma in patients with HCV-related advanced chronic liver disease after oral antivirals.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30196.
    >> Share

  298. MAK LY, Wan-Hin Hui R, Fung J, Liu F, et al
    Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30361.
    >> Share

  299. MAK LY, Ka-Ho Wong D, Pollicino T, Raimondo G, et al
    Occult hepatitis B infection and hepatocellular carcinoma: epidemiology, virology, hepatocarcinogenesis and clinical significance.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30357.
    >> Share

  300. GENESCA J
    Reply to: "Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?" and "External validation of noninvasive predictors of hepatocellular carcinoma in patie
    J Hepatol. 2020 Jun 1. pii: S0168-8278(20)30237.
    >> Share

  301. NABATCHIKOVA E, Abdurakhmanov D, Rozina T, Nikulkina E, et al
    Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?
    J Hepatol. 2020 Jun 1. pii: S0168-8278(20)30197.
    >> Share

  302. EDELINE J, Garin E
    Streamlining TARE or personalizing SIRT? Different philosophies to treat different HCCs with Yttrium-90....
    J Hepatol. 2020;72:1046-1048.
    >> Share

  303. HARMS MH, van Buuren HR, van der Meer AJ
    Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience".
    J Hepatol. 2020;72:1211-1212.
    >> Share

  304. CORPECHOT C, Rousseau A, Chazouilleres O
    Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience.
    J Hepatol. 2020;72:1210-1211.
    >> Share

  305. KHORUTS A, Bajaj JS
    Reply to: " 'You know my name, but not my story' - Deciding on an accurate nomenclature for faecal microbiota transplantation": Intestinal microbiota transplantation: Naming a new paradigm.
    J Hepatol. 2020;72:1213-1214.
    >> Share

  306. PHILIPS CA, Ahamed R, Rajesh S, Augustine P, et al
    'You know my name, but not my story' - Deciding on an accurate nomenclature for faecal microbiota transplantation.
    J Hepatol. 2020;72:1212-1213.
    >> Share

    May 2020
  307. DE SMET V, Verhulst S, van Grunsven LA
    Single cell RNA sequencing analysis did not predict hepatocyte infection by SARS-CoV-2.
    J Hepatol. 2020 May 27. pii: S0168-8278(20)30349.
    >> Share

  308. LUUKKONEN PK, Juuti A, Sammalkorpi H, Penttila AK, et al
    MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans.
    J Hepatol. 2020 May 26. pii: S0168-8278(20)30234.
    >> Share

  309. KIM N, Seong J
    Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?"
    J Hepatol. 2020 May 25. pii: S0168-8278(20)30229.
    >> Share

  310. CHEW CA, Iyer SG, Chieh Kow AW, Madhavan K, et al
    An international multicentre study of protocols for liver transplantation during a pandemic: A case for quadripartite equipoise.
    J Hepatol. 2020 May 23. pii: S0168-8278(20)30342.
    >> Share

  311. TELLEZ L, Ibanez-Samaniego L, Perez Del Villar C, Yotti R, et al
    Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites.
    J Hepatol. 2020 May 21. pii: S0168-8278(20)30303.
    >> Share

  312. MOON AM, Webb GJ, Aloman C, Armstrong MJ, et al
    High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry.
    J Hepatol. 2020 May 20. pii: S0168-8278(20)30305.
    >> Share

  313. CHAN HL, Wong VW, Yip TC, Wong GL, et al
    Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page".
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30273.
    >> Share

  314. RIOU J, Canivet CM, Boursier J
    Reply to: "Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward".
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30233.
    >> Share

  315. LUCIFORA J, Michelet M, Rivoire M, Protzer U, et al
    Two-dimensional-cultures of primary human hepatocytes allow efficient HBV infection: Old tricks still work!
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30204.
    >> Share

  316. SONNEVELD MJ, Brouwer WP, de Man RA
    Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page?
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30231.
    >> Share

  317. LI W
    Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward.
    J Hepatol. 2020 May 13. pii: S0168-8278(20)30179.
    >> Share

  318. KUMAR A
    Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?
    J Hepatol. 2020 May 11. pii: S0168-8278(20)30175.
    >> Share

  319. PENG ZP, Jiang ZZ, Guo HF, Zhou MM, et al
    Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma.
    J Hepatol. 2020 May 11. pii: S0168-8278(20)30296.
    >> Share

  320. WANG Y, Liu S, Liu H, Li W, et al
    SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.
    J Hepatol. 2020 May 10. pii: S0168-8278(20)30294.
    >> Share

  321. WANG S, Friedman SL
    Hepatic fibrosis: A convergent response to liver injury that is reversible.
    J Hepatol. 2020 May 8. pii: S0168-8278(20)30170.
    >> Share

  322. GAO J, Wei B, de Assuncao TM, Liu Z, et al
    Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.
    J Hepatol. 2020 May 7. pii: S0168-8278(20)30290.
    >> Share

  323. DESAI AP, Knapp SM, Orman ES, Ghabril MS, et al
    Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis - a US population-based study.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30289.
    >> Share

  324. MEYER T
    Stereotactic body radiotherapy for hepatocellular carcinoma - still searching for a role.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30232.
    >> Share

  325. DAI Z, Ott M, Sharma AD
    Equal opportunity offer for all hepatocytes.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30200.
    >> Share

  326. SCHWERBEL K, Kamitz A, Krahmer N, Hallahan N, et al
    Immunity-related GTPase induces lipophagy to prevent excess hepatic lipid accumulation.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30275.
    >> Share

  327. BATES J, Vijayakumar A, Ghoshal S, Marchand B, et al
    Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30281.
    >> Share

  328. ABE H, Schuppan D
    beta-arrestin: Dr Jekyll and Mr Hyde in NASH and fibrosis.
    J Hepatol. 2020;72:813-815.
    >> Share

    April 2020
  329. SERENARI M, Han KH, Ravaioli F, Kim SU, et al
    A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma.
    J Hepatol. 2020 Apr 30. pii: S0168-8278(20)30276.
    >> Share

  330. LEFERE S, Puengel T, Hundertmark J, Penners C, et al
    Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.
    J Hepatol. 2020 Apr 29. pii: S0168-8278(20)30269.
    >> Share

  331. HIRSCH TZ, Negulescu A, Gupta B, Caruso S, et al
    Corrigendum to: "BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA" [J Hepatol (2020) 1-13].
    J Hepatol. 2020 Apr 29. pii: S0168-8278(20)30214.
    >> Share

  332. MAZUMDER NR, Celaj S, Atiemo K, Daud A, et al
    Liver-related mortality is similar among men and women with cirrhosis.
    J Hepatol. 2020 Apr 25. pii: S0168-8278(20)30235.
    >> Share

  333. FORREST E
    Alcohol-related liver disease results in significant long-term mortality irrespective of the presence of steatohepatitis.
    J Hepatol. 2020 Apr 20. pii: S0168-8278(20)30117.
    >> Share

  334. DEGRE D, Stauber RE, Deltenre P, Lackner C, et al
    Reply to: "Alcohol-related liver disease results in significant long-term mortality irrespective of the presence of steatohepatitis".
    J Hepatol. 2020 Apr 20. pii: S0168-8278(20)30199.
    >> Share

  335. OKINA Y, Sato-Matsubara M, Matsubara T, Daikoku A, et al
    TGF-beta-driven reduction of cytoglobin leads to oxidative DNA damage in stellate cells during non-alcoholic steatohepatitis.
    J Hepatol. 2020 Apr 17. pii: S0168-8278(20)30228.
    >> Share

  336. TAPPER EB, Asrani SK
    COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30217.
    >> Share

  337. TAPIAS EA, Ardevol A, Garcia-Guix M, Montanes R, et al
    Short-term hemodynamic effects of beta-blockers influence survival of patients with decompensated cirrhosis.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30211.
    >> Share

  338. ANSTEE QM, Darlay R, Cockell S, Meroni M, et al
    Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30213.
    >> Share

  339. LOPEZ-VICARIO C, Checa A, Urdangarin A, Aguilar F, et al
    Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis.
    J Hepatol. 2020 Apr 12. pii: S0168-8278(20)30208.
    >> Share

  340. PARISINOS CA, Wilman HR, Thomas EL, Kelly M, et al
    Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis.
    J Hepatol. 2020 Apr 2. pii: S0168-8278(20)30194.
    >> Share

  341. CHOUDHARY NS, Saraf N, Saigal S, Soin AS, et al
    Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: Many unresolved issues.
    J Hepatol. 2020 Apr 2. pii: S0168-8278(20)30016.
    >> Share

  342. LEE HA, Kim BK, Kim SU
    Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy.
    J Hepatol. 2020 Apr 1. pii: S0168-8278(20)30121.
    >> Share

  343. GANNE-CARRIE N, Piscaglia F
    Non-enhanced MRI surveillance for HCC: A new tool for all, none or selected patients at risk?
    J Hepatol. 2020;72:607-609.
    >> Share

  344. ENGELMANN C, Mehta G, Tacke F
    Regeneration in acute-on-chronic liver failure - the phantom lost its camouflage.
    J Hepatol. 2020;72:610-612.
    >> Share

    March 2020
  345. VERNA EC, Morelli G, Terrault NA, Lok AS, et al
    DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30193.
    >> Share

  346. SANGIOVANNI A, Alimenti E, Gattai R, Filomia R, et al
    Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30192.
    >> Share

  347. LAI JC, Dodge JL, Kappus MR, Dunn MA, et al
    Changes in frailty are associated with waitlist mortality in patients with cirrhosis.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30191.
    >> Share

  348. BERNSMEIER C, van der Merwe S, Perianin A
    The innate immune cells in cirrhosis.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30189.
    >> Share

  349. CARRILLO-REIXACH J, Torrens L, Simon-Coma M, Royo L, et al
    Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30187.
    >> Share

  350. NEWSOME PN, Palmer M, Freilich B, Sheikh MY, et al
    Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
    J Hepatol. 2020 Mar 28. pii: S0168-8278(20)30186.
    >> Share

  351. PAPATHEODORIDIS GV, Lampertico P
    Reply to: "Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy".
    J Hepatol. 2020 Mar 27. pii: S0168-8278(20)30173.
    >> Share

  352. PARK HJ, Jang HY, Kim SY
    Reply to: "Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: Many unresolved issues".
    J Hepatol. 2020 Mar 26. pii: S0168-8278(20)30162.
    >> Share

  353. KHAN SA, Clements O, Kim JU, Eliahoo J, et al
    Reply to: 'Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis]'.
    J Hepatol. 2020 Mar 23. pii: S0168-8278(20)30128.
    >> Share

  354. HASSAN M, Moghadamrad S, Sorribas M, Muntet SG, et al
    Paneth cells promote angiogenesis and regulate portal hypertension in response to microbial signals.
    J Hepatol. 2020 Mar 20. pii: S0168-8278(20)30178.
    >> Share

  355. CUCCHETTI A, Serenari M, Sposito C, Di Sandro S, et al
    Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
    J Hepatol. 2020 Mar 19. pii: S0168-8278(20)30177.
    >> Share

  356. FRANCOZ C
    Acute kidney injury in cirrhosis: An immediate threat but also a ticking time bomb.
    J Hepatol. 2020 Mar 17. pii: S0168-8278(20)30113.
    >> Share

  357. JIANG M, Deng H, Liu S, Su S, et al
    Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis].
    J Hepatol. 2020 Mar 17. pii: S0168-8278(20)30067.
    >> Share

  358. MOREAU R, Claria J, Aguilar F, Fenaille F, et al
    Correction to 'Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF' [J Hepatol 2020 (72) 688-701].
    J Hepatol. 2020 Mar 16. pii: S0168-8278(20)30131.
    >> Share

  359. KIM N, Cheng J, Jung I, Liang J, et al
    Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
    J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30163.
    >> Share

  360. ALFAIATE D, Clement S, Gomes D, Goossens N, et al
    Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
    J Hepatol. 2020 Mar 6. pii: S0168-8278(20)30129.
    >> Share

  361. HARRISON SA, Wai-Sun Wong V, Okanoue T, Bzowej N, et al
    Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials.
    J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126.
    >> Share

  362. GABR A, Ranganathan S, Mouli S, Riaz A, et al
    Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating the lung shunt study.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30122.
    >> Share

  363. LIU Q, Yu J, Wang L, Tang Y, et al
    Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis.
    J Hepatol. 2020 Mar 2. pii: S0168-8278(20)30124.
    >> Share

  364. WONG VW
    Predicting NASH response with liver fat: Are we back to square one?
    J Hepatol. 2020;72:386-388.
    >> Share

    February 2020
  365. BERARDI G, Troisi RI
    Reply to: "Nomogram to predict surgical hepatocellular carcinoma with Child-Pugh B: Feasibility and overlooked predictors".
    J Hepatol. 2020 Feb 28. pii: S0168-8278(20)30069.
    >> Share

  366. BANSAL R
    Battling IL-17, the troublemaker in alcohol-induced hepatocellular carcinoma.
    J Hepatol. 2020 Feb 28. pii: S0168-8278(20)30109.
    >> Share

  367. HUO TI, Liu PH, Hsu CY
    Nomogram to predict surgical hepatocellular carcinoma with Child-Pugh B: Feasibility and overlooked predictors.
    J Hepatol. 2020 Feb 28. pii: S0168-8278(20)30015.
    >> Share

  368. ARFIANTI A, Pok S, Barn V, Haigh WG, et al
    Exercise retards hepatocarcinogenesis in obese mice independently of weight control.
    J Hepatol. 2020 Feb 20. pii: S0168-8278(20)30104.
    >> Share

  369. STADELMAYER B, Diederichs A, Chapus F, Rivoire M, et al
    Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum.
    J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30102.
    >> Share

  370. ARAB JP, Cabrera D, Sehrawat TS, Jalan-Sakrikar N, et al
    Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12.
    J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30103.
    >> Share

  371. HE F, Antonucci L, Yamachika S, Zhang Z, et al
    NRF2 Activates Growth Factor Genes and Downstream AKT Signaling to Induce Mouse and Human Hepatomegaly.
    J Hepatol. 2020 Feb 12. pii: S0168-8278(20)30070.
    >> Share

  372. MULLER M, Bird TG, Nault JC
    The landscape of gene mutations in cirrhosis and hepatocellular carcinoma.
    J Hepatol. 2020 Feb 7. pii: S0168-8278(20)30060.
    >> Share

  373. MAZZAFERRO V, Gorgen A, Roayaie S, Droz Dit Busset M, et al
    Liver resection and transplantation for intrahepatic cholangiocarcinoma.
    J Hepatol. 2020;72:364-377.
    >> Share

  374. KELLEY RK, Bridgewater J, Gores GJ, Zhu AX, et al
    Systemic therapies for intrahepatic cholangiocarcinoma.
    J Hepatol. 2020;72:353-363.
    >> Share

  375. SANGRO B, Chan SL, Meyer T, Reig M, et al
    Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
    J Hepatol. 2020;72:320-341.
    >> Share

  376. CHENG AL, Hsu C, Chan SL, Choo SP, et al
    Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
    J Hepatol. 2020;72:307-319.
    >> Share

  377. VIBERT E, Schwartz M, Olthoff KM
    Advances in resection and transplantation for hepatocellular carcinoma.
    J Hepatol. 2020;72:262-276.
    >> Share

  378. SINGAL AG, Lampertico P, Nahon P
    Epidemiology and surveillance for hepatocellular carcinoma: New trends.
    J Hepatol. 2020;72:250-261.
    >> Share

  379. REBOUISSOU S, Nault JC
    Advances in molecular classification and precision oncology in hepatocellular carcinoma.
    J Hepatol. 2020;72:215-229.
    >> Share

    January 2020
  380. TSENG TC, Liu CJ, Chang CT, Su TH, et al
    HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis.
    J Hepatol. 2020 Jan 29. pii: S0168-8278(20)30029.
    >> Share

  381. BAJAJ JS, Khoruts A
    Microbiota changes and Intestinal Microbiota Transplantation in Liver Diseases and Cirrhosis.
    J Hepatol. 2020 Jan 28. pii: S0168-8278(20)30058.
    >> Share

  382. PAPATHEODORIDIS GV, Sypsa V, Dalekos GN, Yurdaydin C, et al
    Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Jan 22. pii: S0168-8278(20)30022.
    >> Share

  383. DEGRE D, Stauber RE, Englebert G, Sarocchi F, et al
    Long-term outcome of decompensated alcohol-related liver disease with steatohepatitis and Maddrey's discriminant function <32.
    J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30014.
    >> Share

  384. NAMINENI S, O'Connor T, Faure-Dupuy S, Johansen P, et al
    A dual role for hepatocyte-intrinsic canonical NF-kappaB signaling in virus control.
    J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30010.
    >> Share

  385. PRAKTIKNJO M, Simon-Talero M, Romer J, Roccarina D, et al
    Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.
    J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30012.
    >> Share

  386. KOWALIK MA, Puliga E, Cabras L, Sulas P, et al
    Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming.
    J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30009.
    >> Share

  387. BASSEGODA O, Huelin P, Ariza X, Sole C, et al
    DEVELOPMENT OF CHRONIC KIDNEY DISEASE AFTER ACUTE KIDNEY INJURY IN PATIENTS WITH CIRRHOSIS IS COMMON AND IMPAIRS CLINICAL OUTCOMES.
    J Hepatol. 2020 Jan 14. pii: S0168-8278(20)30011.
    >> Share

  388. BUREAU C, Adebayo D, Chalret de Rieu M, Elkrief L, et al
    Corrigendum to 'Alfapump(R) system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study' [J Hepatol 67 (2017) 940-949].
    J Hepatol. 2020 Jan 9. pii: S0168-8278(19)30723.
    >> Share

  389. HAZARI Y, Bravo-San Pedro JM, Hetz C, Galluzzi L, et al
    Autophagy in hepatic adaptation to stress.
    J Hepatol. 2020;72:183-196.
    >> Share

    December 2019
  390. MA HY, Yamamoto G, Xu J, Liu X, et al
    IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.
    J Hepatol. 2019 Dec 31. pii: S0168-8278(19)30761.
    >> Share

  391. DAI WQ, Xu L, Yu XN, Zhang GC, et al
    OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    J Hepatol. 2019 Dec 30. pii: S0168-8278(19)30760.
    >> Share

  392. DE VRIES E, Beuers U
    Reply to: "UDCA therapy in intrahepatic cholestasis of pregnancy?"
    J Hepatol. 2019 Dec 28. pii: S0168-8278(19)30705.
    >> Share

  393. DONG LQ, Peng LH, Ma LJ, Liu DB, et al
    Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
    J Hepatol. 2019 Dec 27. pii: S0168-8278(19)30759.
    >> Share

  394. PAISANT A, Vilgrain V, Riou J, Oberti F, et al
    Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30725.
    >> Share

  395. GARCIA-TSAO G, Bosch J, Kayali Z, Harrison SA, et al
    Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30724.
    >> Share

  396. KUMAR P, Kulkarni A
    UDCA therapy in intrahepatic cholestasis of pregnancy?
    J Hepatol. 2019 Dec 18. pii: S0168-8278(19)30653.
    >> Share

  397. HIRSCH TZ, Negulescu A, Gupta B, Caruso S, et al
    BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
    J Hepatol. 2019 Dec 17. pii: S0168-8278(19)30718.
    >> Share

  398. ZHANG Z, Xu X, Tian W, Jiang R, et al
    ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation.
    J Hepatol. 2019 Dec 16. pii: S0168-8278(19)30716.
    >> Share

  399. CHEUK-FUNG YIP T, Lai-Hung Wong G, Wai-Sun Wong V, Tse YK, et al
    Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
    J Hepatol. 2019 Dec 16. pii: S0168-8278(19)30717.
    >> Share

  400. DHAWAN A, Chaijitraruch N, Fitzpatrick E, Bansal S, et al
    Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children.
    J Hepatol. 2019 Dec 13. pii: S0168-8278(19)30714.
    >> Share

  401. PEI T, Meng F, Xiao P, Han J, et al
    MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    J Hepatol. 2019 Dec 11. pii: S0168-8278(19)30713.
    >> Share

  402. PARK HJ, Jang HY, Kim SY, Lee SJ, et al
    Non-enhanced Magnetic Resonance Imaging as a Surveillance Tool for Hepatocellular Carcinoma: Comparison with Ultrasound.
    J Hepatol. 2019 Dec 10. pii: S0168-8278(19)30712.
    >> Share

  403. SOLE C, Sola E, Kamath PS, Gines P, et al
    Lack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosis.
    J Hepatol. 2019 Dec 10. pii: S0168-8278(19)30554.
    >> Share

  404. SHE S, Wu X, Zheng D, Pei X, et al
    PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target.
    J Hepatol. 2019 Dec 5. pii: S0168-8278(19)30654.
    >> Share

  405. GARCIA-TSAO G, Angeli P, Nadim MK, Parikh CR, et al
    Reply to: "Lack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosis".
    J Hepatol. 2019 Dec 3. pii: S0168-8278(19)30673.
    >> Share

  406. JALAN R, Bataller R, Berg T, Lotersztajn S, et al
    Journal of Hepatology: The Home of Liver Research, 2015-2019.
    J Hepatol. 2019;71:1065-1069.
    >> Share

    November 2019
  407. CUCCHETTI A, Zhong J, Berhane S, Toyoda H, et al
    The chances of hepatic resection curing hepatocellular carcinoma.
    J Hepatol. 2019 Nov 29. pii: S0168-8278(19)30703.
    >> Share

  408. BONNIN M, Fares N, Testoni B, Estornes Y, et al
    Corrigendum to "Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis" [J Hepatol 71 (2019) 763-772].
    J Hepatol. 2019 Nov 25. pii: S0168-8278(19)30651.
    >> Share

  409. CHIEW AL, James LP, Isbister GK, Pickering JW, et al
    Early Acetaminophen-Protein Adducts Predict Hepatotoxicity Following Overdose.
    J Hepatol. 2019 Nov 21. pii: S0168-8278(19)30677.
    >> Share

  410. HE X, Wang Y, Fan X, Lei N, et al
    A schistosome miRNA promotes host hepatic fibrosis by targeting transforming growth factor beta receptor III.
    J Hepatol. 2019 Nov 15. pii: S0168-8278(19)30674.
    >> Share

  411. HAMMOUTENE A, Biquard L, Lasselin J, Kheloufi M, et al
    A defect in endothelial autophagy occurs in patients with nonalcoholic steatohepatitis and promotes inflammation and fibrosis.
    J Hepatol. 2019 Nov 11. pii: S0168-8278(19)30669.
    >> Share

  412. FERENCI P
    Are all cirrhotic patients equal?
    J Hepatol. 2019 Nov 6. pii: S0168-8278(19)30649.
    >> Share

  413. HARRISON SA, Alkhouri N, Davison BA, Sanyal A, et al
    Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
    J Hepatol. 2019 Nov 4. pii: S0168-8278(19)30650.
    >> Share

  414. BROWN RS JR, Buti M, Rodrigues L, Chulanov V, et al
    Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial.
    J Hepatol. 2019 Nov 1. pii: S0168-8278(19)30647.
    >> Share

    October 2019
  415. BERNAL W, Caldwell SH, Lisman T
    Nails in the coffin of fresh frozen plasma to prevent or treat bleeding in cirrhosis?
    J Hepatol. 2019 Oct 29. pii: S0168-8278(19)30590.
    >> Share

  416. SUNDARAM V, Kogachi S, Wong RJ, Karvellas CJ, et al
    Effect of the clinical course of acute on chronic liver failure prior to liver transplantation on post-transplant survival.
    J Hepatol. 2019 Oct 25. pii: S0168-8278(19)30640.
    >> Share

  417. YAU T, Hsu C, Kim TY, Choo SP, et al
    Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552].
    J Hepatol. 2019 Oct 24. pii: S0168-8278(19)30551.
    >> Share

  418. SHEN YC, Hsu CL, Jeng YM, Ho MC, et al
    Reliability of a Single-region Sample to evaluate Immune Tumor Microenvironment in Hepatocellular Carcinoma.
    J Hepatol. 2019 Oct 18. pii: S0168-8278(19)30608.
    >> Share

  419. SIDDIQUI MS, Van Natta ML, Connelly MA, Vuppalanchi R, et al
    Impact of Obeticholic Acid on the Lipoprotein Profile in Patients with Nonalcoholic Steatohepatitis.
    J Hepatol. 2019 Oct 18. pii: S0168-8278(19)30607.
    >> Share

  420. GIANNELLI V, Roux O, Laouenan C, Manchon P, et al
    Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation.
    J Hepatol. 2019 Oct 14. pii: S0168-8278(19)30603.
    >> Share

  421. LI Y, Tang L, Guo L, Chen C, et al
    CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+T cells favors viral control in chronic HBV infection.
    J Hepatol. 2019 Oct 11. pii: S0168-8278(19)30602.
    >> Share

  422. BRIL F, Barb D, Lomonaco R, Lai J, et al
    Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    J Hepatol. 2019 Oct 4. pii: S0168-8278(19)30584.
    >> Share

    September 2019
  423. JIANG F, Chen Q, Wang W, Ling Y, et al
    Hepatocyte-Derived Extracellular Vesicles Promote Endothelial Inflammation and Atherogenesis via microRNA-1.
    J Hepatol. 2019 Sep 27. pii: S0168-8278(19)30552.
    >> Share

  424. BERTUCCIO P, Malvezzi M, Carioli G, Hashim D, et al
    Reply to: "Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma".
    J Hepatol. 2019 Sep 26. pii: S0168-8278(19)30527.
    >> Share

  425. MARTIN MATEOS R, Maddur H
    A step forward to accurately predict mortality in cirrhotic patients undergoing elective surgery: The role of the hepatic venous pressure gradient.
    J Hepatol. 2019 Sep 23. pii: S0168-8278(19)30529.
    >> Share

  426. KHAN SA, Genus T, Morement H, Murphy A, et al
    Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.
    J Hepatol. 2019 Sep 23. pii: S0168-8278(19)30466.
    >> Share

  427. GASPERSZ MP, Klompenhouwer AJ, Broker MEE, Thomeer MGJ, et al
    Growth of hepatocellular adenoma during pregnancy: a prospective study.
    J Hepatol. 2019 Sep 21. pii: S0168-8278(19)30548.
    >> Share

  428. TOH TB, Lim JJ, Hooi L, Rashid MBMA, et al
    Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/beta-catenin-driven hepatocellular carcinoma.
    J Hepatol. 2019 Sep 18. pii: S0168-8278(19)30547.
    >> Share

  429. VITALE A, Majno-Hurst P
    Towards a personalized approach to hepatic resection in cirrhotic patients.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30541.
    >> Share

  430. CLEMENTS O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al
    Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30543.
    >> Share

  431. RASSI AB, d'Amico EA, Tripodi A, Rocha TRFD, et al
    Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: effect on conventional coagulation tests and thrombomodulin-modified thrombin generation.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30544.
    >> Share

  432. TSCHUOR C, Kummerli C, Dutkowski P, Hernandez-Alejandro R, et al
    Reply to: "Canadian liver transplant allocation for hepatocellular carcinoma".
    J Hepatol. 2019 Sep 7. pii: S0168-8278(19)30463.
    >> Share

  433. MCLIN VA, Braissant O, Cudalbu C
    Reply to: "Magnetic resonance spectroscopy: A surrogate marker of hepatic encephalopathy?"
    J Hepatol. 2019 Sep 6. pii: S0168-8278(19)30469.
    >> Share

  434. HERMANN B, Rudler M, Galanaud D, Thabut D, et al
    Magnetic resonance spectroscopy: A surrogate marker of hepatic encephalopathy?
    J Hepatol. 2019 Sep 6. pii: S0168-8278(19)30416.
    >> Share

  435. BERARDI G, Morise Z, Sposito C, Igarashi K, et al
    Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in child-pugh b cirrhosis.
    J Hepatol. 2019 Sep 6. pii: S0168-8278(19)30526.
    >> Share

  436. WEI Y, Shi D, Liang Z, Liu Y, et al
    IL-17A Secreted from Lymphatic Endothelial Cells Promotes Tumorigenesis by Up-regulation of PD-L1 in Hepatoma Stem Cells.
    J Hepatol. 2019 Sep 6. pii: S0168-8278(19)30528.
    >> Share

  437. BRAHMANIA M, Marquez V, Kneteman NM, Bhat M, et al
    Canadian liver transplant allocation for hepatocellular carcinoma.
    J Hepatol. 2019 Sep 5. pii: S0168-8278(19)30425.
    >> Share

    August 2019
  438. TOVOLI F, Ielasi L, Casadei-Gardini A, Granito A, et al
    Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients.
    J Hepatol. 2019 Aug 23. pii: S0168-8278(19)30482.
    >> Share

  439. HOU J, Zhang H, Sun B, Karin M, et al
    The Immunobiology of Hepatocellular Carcinoma in Humans and Mice: Basic Concepts and Therapeutic Implications.
    J Hepatol. 2019 Aug 23. pii: S0168-8278(19)30481.
    >> Share

  440. BHANGUI P, Lim C, Levesque E, Salloum C, et al
    Novel Classification of Nonmalignant Portal Vein Thrombosis: A guide to Surgical Decision Making during Liver Transplantation.
    J Hepatol. 2019 Aug 20. pii: S0168-8278(19)30479.
    >> Share

  441. RICKE J, Klumpen HJ, Amthauer H, Bargellini I, et al
    Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
    J Hepatol. 2019 Aug 14. pii: S0168-8278(19)30472.
    >> Share

  442. MOURIES J, Brescia P, Silvestri A, Spadoni I, et al
    Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    J Hepatol. 2019 Aug 13. pii: S0168-8278(19)30471.
    >> Share

  443. KIM BK
    Reply to: "Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction".
    J Hepatol. 2019 Aug 2. pii: S0168-8278(19)30412.
    >> Share

  444. HAKIM A, Mistry PK, Vilarinho S
    Reply to: "Whole exome sequencing for personalized hepatology: Expanding applications in adults and challenges".
    J Hepatol. 2019 Aug 1. pii: S0168-8278(19)30413.
    >> Share

    July 2019
  445. VALENTI L, Pelusi S, Baselli G
    Whole exome sequencing for personalized hepatology: Expanding applications in adults and challenges.
    J Hepatol. 2019 Jul 27. pii: S0168-8278(19)30355.
    >> Share

  446. MORAIS R, Liberal R, Santos A, Pita I, et al
    Another clinical unmet need in liver patients: Multidrug resistant bacteria in decompensated cirrhosis.
    J Hepatol. 2019 Jul 27. pii: S0168-8278(19)30357.
    >> Share

  447. CHOI J, Lim YS
    Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction.
    J Hepatol. 2019 Jul 24. pii: S0168-8278(19)30385.
    >> Share

  448. HERNANDEZ-TEJERO M, Triolo M, Fernandez J
    Reply to: "Another clinical unmet need in liver patients: Multidrug-resistant bacteria in decompensated cirrhosis".
    J Hepatol. 2019 Jul 24. pii: S0168-8278(19)30403.
    >> Share

  449. ZHOU SL, Zhou ZJ, Hu ZQ, Song CL, et al
    Genomic Sequencing Identifies WNK2 as a Driver in hepatocellular carcinoma and a Risk Factor for Early Recurrence.
    J Hepatol. 2019 Jul 23. pii: S0168-8278(19)30423.
    >> Share

  450. FAURE-DUPUY S, Delphin M, Aillot L, Dimier L, et al
    Hepatitis B Virus-induced modulation of liver macrophage function promotes hepatocyte infection.
    J Hepatol. 2019 Jul 23. pii: S0168-8278(19)30422.
    >> Share

  451. REVERTER E, Cirera I, Albillos A, Debernardi-Venon W, et al
    The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery.
    J Hepatol. 2019 Jul 19. pii: S0168-8278(19)30415.
    >> Share

  452. LOGLIO A, Ferenci P, Colonia Uceda Renteria S, Tham CYL, et al
    Excellent safety and effectiveness of high dose myrcludex-b monotherapy administered for 48 weeks in hdv related compensated cirrhosis: a case report of three patients.
    J Hepatol. 2019 Jul 11. pii: S0168-8278(19)30411.
    >> Share

  453. ANGELI P, Garcia-Tsao G, Nadim MK, Parikh CR, et al
    News in Pathophysiology, Definition and Classification of Hepatorenal Syndrome: a step beyond the International Club of Ascites (ICA) Consensus document.
    J Hepatol. 2019 Jul 11. pii: S0168-8278(19)30410.
    >> Share

  454. MUN SJ, Ryu JS, Lee MO, Son YS, et al
    Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids.
    J Hepatol. 2019 Jul 9. pii: S0168-8278(19)30402.
    >> Share

  455. SORRIBAS M, Jakob MO, Yilmaz B, Li H, et al
    FxR-modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
    J Hepatol. 2019 Jul 8. pii: S0168-8278(19)30389.
    >> Share

  456. GORG B, Karababa A, Schutz E, Paluschinski M, et al
    O-GlcNAcylation-dependent upregulation of HO1 triggers ammonia-induced oxidative stress and senescence in hepatic encephalopathy.
    J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30392.
    >> Share

    June 2019
  457. AL-DURY S, Wahlstrom A, Panzitt K, Thorell A, et al
    Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
    J Hepatol. 2019 Jun 26. pii: S0168-8278(19)30383.
    >> Share

  458. MAJUMDAR A, Roberts SK, Pilcher D
    Are liver transplant centres critical for the critically ill patient with cirrhosis?
    J Hepatol. 2019 Jun 21. pii: S0168-8278(19)30288.
    >> Share

  459. DURAND F, Pavesi M, Cheung R
    Liver transplantation for non-alcoholic steatohepatitis in Europe: Where do we stand?
    J Hepatol. 2019 Jun 19. pii: S0168-8278(19)30304.
    >> Share

  460. RYAN MC, Zelber-Sagi S
    Hepatic fat: Pathogenic trigger or passenger?
    J Hepatol. 2019 Jun 18. pii: S0168-8278(19)30302.
    >> Share

  461. BORST K, Graalmann T, Kalinke U
    Reply to: "Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtype-specific markers".
    J Hepatol. 2019 Jun 18. pii: S0168-8278(19)30298.
    >> Share

  462. BONNIN M, Fares N, Testoni B, Estornes Y, et al
    KfouryToll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis.
    J Hepatol. 2019 Jun 17. pii: S0168-8278(19)30351.
    >> Share

  463. LEFERE S, Degroote H, Van Vlierberghe H, Devisscher L, et al
    Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtype-specific markers.
    J Hepatol. 2019 Jun 15. pii: S0168-8278(19)30187.
    >> Share

  464. O'ROURKE JM, Patten DA, Shetty S
    Tumour-associated macrophages in hepatocellular carcinoma: Pressing the metabolic switch to prevent T cell responses.
    J Hepatol. 2019 Jun 14. pii: S0168-8278(19)30305.
    >> Share

  465. PRODEAU M, Drumez E, Duhamel A, Vibert E, et al
    An Ordinal Model to Predict the Risk of Symptomatic Liver Failure in Patients with Cirrhosis undergoing Hepatectomy.
    J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30346.
    >> Share

  466. LIU Y, Lu T, Zhang C, Xu J, et al
    Activation of YAP Attenuates Hepatic Damage and Fibrosis in Liver Ischemia-Reperfusion Injury.
    J Hepatol. 2019 Jun 12. pii: S0168-8278(19)30344.
    >> Share

  467. WANG J, Wang H, Peters M, Ding N, et al
    Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis.
    J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30342.
    >> Share

  468. SAPENA V, Rios J, Torres F, Marino Z, et al
    Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response".
    J Hepatol. 2019 Jun 7. pii: S0168-8278(19)30280.
    >> Share

  469. YAU T, Hsu C, Kim TY, Choo SP, et al
    Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis.
    J Hepatol. 2019 Jun 6. pii: S0168-8278(19)30300.
    >> Share

  470. WANG X, He Q, Shen H, Xia A, et al
    TOX promotes the exhaustion of antitumor CD8(+) T cells by preventing PD1 degradation in hepatocellular carcinoma.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30301.
    >> Share

  471. BRAISSANT O, Rackayova V, Pierzchala K, Grosse J, et al
    Longitudinal neurometabolic changes in the hippocampus of a rat model of chronic hepatic encephalopathy.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30308.
    >> Share

  472. YANG S, Wang L, Pan W, Bayer W, et al
    MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30299.
    >> Share

  473. RAVICHANDRAN G, Neumann K, Berkhout LK, Weidemann S, et al
    Interferon-gamma-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30309.
    >> Share

    May 2019
  474. DE TYMOWSKI C, Depret F, Soussi S, Nabila M, et al
    Contributing factors and outcomes of burn-associated cholestasis.
    J Hepatol. 2019 May 29. pii: S0168-8278(19)30292.
    >> Share

  475. IOANNOU GN, Green P, Kerr KF, Berry K, et al
    Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
    J Hepatol. 2019 May 27. pii: S0168-8278(19)30291.
    >> Share

  476. POL S, Fontaine H, Carrat F
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response.
    J Hepatol. 2019 May 23. pii: S0168-8278(19)30186.
    >> Share

  477. JOUVE JL, Lecomte T, Bouche O, Barbier E, et al
    Pravastatin combination with Sorafenib does not improve survival in advanced Hepatocellular Carcinoma.
    J Hepatol. 2019 May 21. pii: S0168-8278(19)30289.
    >> Share

  478. KIM DH, Choi SH, Byun JH, Kang JH, et al
    Arterial Subtraction Images of Gadoxetate-Enhanced MRI Improve Diagnosis of Early-Stage Hepatocellular Carcinoma.
    J Hepatol. 2019 May 17. pii: S0168-8278(19)30286.
    >> Share

  479. FONTANELLAS A, Avila MA, Anderson KE, Deybach JC, et al
    Current and innovative emerging therapies for porphyrias with hepatic involvement.
    J Hepatol. 2019 May 15. pii: S0168-8278(19)30282.
    >> Share

  480. JI F, Yeo YH, Wei MT, Ogawa E, et al
    Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
    J Hepatol. 2019 May 13. pii: S0168-8278(19)30279.
    >> Share

  481. GEPNER Y, Shelef I, Komy O, Cohen N, et al
    The Beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content.
    J Hepatol. 2019 May 7. pii: S0168-8278(19)30274.
    >> Share

  482. NISHIO T, Hu R, Koyama Y, Liang S, et al
    Activated Hepatic Stellate Cells and Portal Fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice.
    J Hepatol. 2019 May 6. pii: S0168-8278(19)30273.
    >> Share

  483. HALDAR D, Kern B, Hodson J, James Armstrong M, et al
    Outcomes of Liver Transplantation for Non-alcoholic Steatohepatitis: a European Liver Transplant Registry Study.
    J Hepatol. 2019 May 6. pii: S0168-8278(19)30272.
    >> Share

  484. CHEN DP, Ning WR, Jiang ZZ, Peng ZP, et al
    Glycolytic Activation of Peritumoral Monocytes Fosters Immune Privilege via PFKFB3-PD-L1 axis in Human Hepatocellular Carcinoma.
    J Hepatol. 2019 May 6. pii: S0168-8278(19)30268.
    >> Share

  485. GALLINA P, Gallo O, Nicoletti C, Romanelli RG, et al
    A hydrodynamic hypothesis for the pathogenesis of glymphatic system impairment in hepatic encephalopathy.
    J Hepatol. 2019 May 3. pii: S0168-8278(19)30124.
    >> Share

    April 2019
  486. OTT M, Castell JV
    Hepatocyte transplantation, a step forward?
    J Hepatol. 2019 Apr 17. pii: S0168-8278(19)30193.
    >> Share

  487. ALEKSIEVA N, Forbes SJ
    Biliary-derived hepatocytes in chronic liver injury: Bringing new troops to the battlefield?
    J Hepatol. 2019 Apr 10. pii: S0168-8278(19)30185.
    >> Share

  488. HARMS MH, van Buuren HR, Corpechot C, Thorburn D, et al
    Ursodeoxycholic Acid Therapy and Liver Transplant-free Survival in Patients with Primary Biliary Cholangitis.
    J Hepatol. 2019 Apr 10. pii: S0168-8278(19)30228.
    >> Share

  489. OVEREEM AW, Klappe K, Parisi S, Kloters-Planchy P, et al
    Pluripotent stem cell-derived bile canaliculi-forming hepatocytes to study genetic liver diseases involving hepatocyte polarity.
    J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30225.
    >> Share

  490. WANDELER G, Mauron E, Atkinson A, Dufour JF, et al
    Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies.
    J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30226.
    >> Share

  491. CABIBBO G, Celsa C, Calvaruso V, Petta S, et al
    Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    J Hepatol. 2019 Apr 5. pii: S0168-8278(19)30221.
    >> Share

  492. GERARD C, Di-Luoffo M, Gonay L, Caruso S, et al
    Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma.
    J Hepatol. 2019 Apr 3. pii: S0168-8278(19)30195.
    >> Share

    March 2019
  493. ARONSON SJ, Bakker RS, Shi X, Duijst S, et al
    Liver-directed gene therapy results in long term correction of progressive familial intrahepatic cholestasis type 3 in mice.
    J Hepatol. 2019 Mar 29. pii: S0168-8278(19)30192.
    >> Share

  494. JEONG KANG H, Oh JH, Chun SM, Kim D, et al
    Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.
    J Hepatol. 2019 Mar 28. pii: S0168-8278(19)30189.
    >> Share

  495. ZHANG X, Fan L, Wu J, Xu H, et al
    Macrophage p38alpha promotes nutritional steatohepatitis through M1 polarization.
    J Hepatol. 2019 Mar 23. pii: S0168-8278(19)30184.
    >> Share

  496. BERTUCCIO P, Malvezzi M, Carioli G, Hashim D, et al
    Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.
    J Hepatol. 2019 Mar 22. pii: S0168-8278(19)30183.
    >> Share

  497. TSUNODA T, Kakinuma S, Miyoshi M, Kamiya A, et al
    Loss of Fibrocystin Promotes Interleukin-8-Dependent Proliferation and CTGF Production of Biliary Epithelium.
    J Hepatol. 2019 Mar 15. pii: S0168-8278(19)30146.
    >> Share

  498. BAYO J, Fiore EJ, Dominguez LM, Real A, et al
    A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
    J Hepatol. 2019 Mar 14. pii: S0168-8278(19)30148.
    >> Share

  499. XU X, Zhang HL, Liu QP, Sun SW, et al
    Radiomic Analysis of Contrast-Enhanced CT Predicts Microvascular Invasion and Outcome in Hepatocellular Carcinoma.
    J Hepatol. 2019 Mar 12. pii: S0168-8278(19)30145.
    >> Share

  500. JAIN V, Burford C, Alexander EC, Sutton H, et al
    Prognostic markers at adolescence in patients Biliary Atresia for liver transplantation in adulthood.
    J Hepatol. 2019 Mar 12. pii: S0168-8278(19)30143.
    >> Share

  501. MEYER T, Johnson P
    Trial endpoints for systemic therapy in patients with hepatocellular carcinoma.
    J Hepatol. 2019 Mar 11. pii: S0168-8278(19)30137.
    >> Share

  502. FRANCOZ C, Sola E
    Assessment of renal function in cirrhosis: Sarcopenia, gender and ethnicity matter.
    J Hepatol. 2019 Mar 1. pii: S0168-8278(19)30118.
    >> Share

  503. YAN WT, Quan B, Xing H, Wu MC, et al
    Time to recurrence, but not recurrence-free survival, should be the endpoint used to predict early recurrence after HCC resection.
    J Hepatol. 2019;70:570-571.
    >> Share

    February 2019
  504. HERNANDEZ-GEA V, Gottardi A, Leebeek FWG, Rautou PE, et al
    Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis.
    J Hepatol. 2019 Feb 26. pii: S0168-8278(19)30130.
    >> Share

  505. MANCO R, Clerbaux LA, Verhulst S, Nader MB, et al
    Reactive cholangiocytes differentiate into proliferative hepatocytes with efficient DNA repair in mice with chronic liver injury.
    J Hepatol. 2019 Feb 19. pii: S0168-8278(19)30117.
    >> Share

  506. DEVARBHAVI H, Asrani SK, Kamath PS
    Reply to: "Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia".
    J Hepatol. 2019 Feb 19. pii: S0168-8278(19)30066.
    >> Share

  507. SINGH SP, Panigrahi S, Mishra D, Khatua CR, et al
    Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia.
    J Hepatol. 2019 Feb 16. pii: S0168-8278(19)30012.
    >> Share

  508. HOUGHTON D, Zalewski P, Hallsworth K, Cassidy S, et al
    The degree of hepatic steatosis associates with impaired cardiac and autonomic function.
    J Hepatol. 2019 Feb 12. pii: S0168-8278(19)30112.
    >> Share

  509. TAPPER EB, Romero-Gomez M, Bajaj JS
    Hepatic encephalopathy and traffic accidents: Vigilance is needed!
    J Hepatol. 2019 Feb 11. pii: S0168-8278(19)30031.
    >> Share


  510. Corrigendum to "EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma" [J Hepatol 69 (2018) 182-236].
    J Hepatol. 2019 Feb 7. pii: S0168-8278(19)30034.
    >> Share

  511. MORTON A
    Splenic artery aneurysms, portal hypertension and pregnancy.
    J Hepatol. 2019 Feb 4. pii: S0168-8278(18)32638.
    >> Share

  512. ANDRADE F, Shukla A, Bureau C, Senzolo M, et al
    Reply to: ''Splenic artery aneurysms, portal hypertension and pregnancy".
    J Hepatol. 2019 Feb 4. pii: S0168-8278(19)30017.
    >> Share

  513. GANNE-CARRIE N, Nahon P
    Hepatocellular carcinoma in the setting of alcohol-related liver disease.
    J Hepatol. 2019;70:284-293.
    >> Share

  514. GAO B, Ahmad MF, Nagy LE, Tsukamoto H, et al
    Inflammatory pathways in alcoholic steatohepatitis.
    J Hepatol. 2019;70:249-259.
    >> Share

  515. BELDI G, Vuitton D, Lachenmayer A, Heyd B, et al
    Is ex vivo liver resection and autotransplantation a valid alternative treatment for end-stage hepatic alveolar echinococcosis in Europe?
    J Hepatol. 2019 Feb 1. pii: S0168-8278(18)32630.
    >> Share

    January 2019
  516. BORST K, Graalmann T, Kalinke U
    Reply to: "Lack of Kupffer cell depletion in diethylnitrosamine-induced hepatic inflammation".
    J Hepatol. 2019 Jan 31. pii: S0168-8278(19)30013.
    >> Share

  517. SOLA E, Sole C, Gines P
    Reply to: "Midodrine and albumin in decompensated cirrhosis: Down but not out...".
    J Hepatol. 2019 Jan 30. pii: S0168-8278(18)32646.
    >> Share

  518. SANZ-GARCIA C, Poulsen KL, Bellos D, Wang H, et al
    The non-transcriptional activity of IRF3 modulates hepatic immune cell populations in acute on chronic ethanol administration in mice.
    J Hepatol. 2019 Jan 30. pii: S0168-8278(19)30064.
    >> Share

  519. KESSLER SM, Hoppstadter J, Hosseini K, Laggai S, et al
    Lack of Kupffer cell depletion in diethylnitrosamine-induced hepatic inflammation.
    J Hepatol. 2019 Jan 24. pii: S0168-8278(18)32569.
    >> Share

  520. FERRARESE A, Feltracco P, Barbieri S, Cillo U, et al
    Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(18)32389.
    >> Share

  521. VAN DER MERWE S, Laleman W, Langouche L, Meersseman P, et al
    Reply to: "Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF".
    J Hepatol. 2019 Jan 23. pii: S0168-8278(19)30007.
    >> Share

  522. SINGH V, Singh A, Agarwal R
    Midodrine and albumin in decompensated cirrhosis: Down but not out....
    J Hepatol. 2019 Jan 23. pii: S0168-8278(18)32540.
    >> Share

  523. XIANG X, Wang Y, Mo DC, Wang SQ, et al
    Liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection: A comment for moving forward.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(18)32572.
    >> Share

  524. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(19)30015.
    >> Share

  525. WEI W, Li L, Kong G, Zheng Z, et al
    Spleen in hepatocellular carcinoma: More complexity and importance than we knew.
    J Hepatol. 2019 Jan 22. pii: S0168-8278(18)32573.
    >> Share

  526. GRANCINI V, Trombetta M, Lunati ME, Boselli ML, et al
    Central role of the beta-cell in driving regression of diabetes after liver transplantation in cirrhotic patients.
    J Hepatol. 2019 Jan 21. pii: S0168-8278(19)30028.
    >> Share

  527. GWAG T, Meng Z, Sui Y, Helsley RN, et al
    Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis.
    J Hepatol. 2019 Jan 21. pii: S0168-8278(19)30029.
    >> Share

  528. PAUMELLE R, Haas J, Hennuyer N, Bauge E, et al
    Hepatic PPARalpha is critical in the metabolic adaptation to sepsis.
    J Hepatol. 2019 Jan 21. pii: S0168-8278(19)30027.
    >> Share

  529. HUO TI, Liu PH, Hsu CY
    Predicting post-resection recurrence of hepatocellular carcinoma: Spleen stiffness vs. ALBI grade.
    J Hepatol. 2019 Jan 21. pii: S0168-8278(18)32571.
    >> Share

  530. MARASCO G, Colecchia A, Colli A, Ravaioli F, et al
    Reply to correspondence concerning: "Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection".
    J Hepatol. 2019 Jan 17. pii: S0168-8278(18)32645.
    >> Share

  531. WANG Q, Xia D, Bai W, Wang E, et al
    Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study.
    J Hepatol. 2019 Jan 17. pii: S0168-8278(19)30025.
    >> Share

  532. BARAHMAN M, Zhang W, Yaffe Harris H, Aiyer A, et al
    Radiation-primed hepatocyte transplantation in murine monogeneic dyslipidemia normalizes cholesterol and prevents atherosclerosis.
    J Hepatol. 2019 Jan 14. pii: S0168-8278(19)30022.
    >> Share

  533. XU QG, Yuan SX, Tao QF, Yu J, et al
    A novel HBx genotype serves as a preoperative predictor and fails to activate the JAK1/STATs pathway in hepatocellular carcinoma.
    J Hepatol. 2019 Jan 14. pii: S0168-8278(19)30018.
    >> Share

  534. VAN WETTERE M, Purcell Y, Bruno O, Payance A, et al
    Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari.
    J Hepatol. 2019 Jan 14. pii: S0168-8278(19)30021.
    >> Share

  535. HSU YC, Yip TC, Ho HJ, Wong VW, et al
    Corrigendum to "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B" [J Hepatol 69 (2018) 278-285].
    J Hepatol. 2019 Jan 8. pii: S0168-8278(18)32629.
    >> Share

  536. HSU YC, Yip TC, Wong GL, Wu CY, et al
    Reply to: "Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues".
    J Hepatol. 2019 Jan 8. pii: S0168-8278(18)32583.
    >> Share

  537. FORMENTIN C, De Rui M, Zoncape M, Ceccato S, et al
    The Psychomotor Vigilance Task: Role in the Diagnosis of Hepatic Encephalopathy and Relationship with Driving Ability.
    J Hepatol. 2019 Jan 8. pii: S0168-8278(19)30005.
    >> Share

  538. WU F, Wu D, Ren Y, Huang Y, et al
    Generation of hepato-biliary organoids from human induced pluripotent stem cells.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30002.
    >> Share

  539. YOO JJ, Kim SG, Kim YS, Lee B, et al
    Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30004.
    >> Share

  540. GOLDARACENA N, Gorgen A, Doyle A, Hansen BE, et al
    Live Donor Liver Transplantation for Patients with Hepatocellular Carcinoma Offers Increased Survival vs. Deceased Donation.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30003.
    >> Share

  541. TISCHENDORF M, Fuchs A, Zeuzem S, Lange CM, et al
    Use of prothrombin complex concentrates in patients with decompensated liver cirrhosis is associated with thromboembolic events.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(18)32570.
    >> Share

  542. TSAI JF, Perng DS
    Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(18)32546.
    >> Share

  543. ZHANG Y, Pei Y, Chen X, Zhang W, et al
    Treatment for solitary hepatocellular carcinoma ranging from 2 and 5cm: Is the curative effect of no-touch multibipolar radiofrequency ablation comparable to that of surgical resection?
    J Hepatol. 2019 Jan 4. pii: S0168-8278(18)32524.
    >> Share

  544. HADJIHAMBI A, Harrison IF, Costas-Rodriguez M, Vanhaecke F, et al
    Corrigendum to "Impaired brain glymphatic flow in experimental hepatic encephalopathy" [J Hepatol 69 (2019) 40-49].
    J Hepatol. 2019 Jan 4. pii: S0168-8278(18)32631.
    >> Share

  545. QIN JJ, Mao W, Wang X, Sun P, et al
    Corrigendum to "Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1" [J Hepatol 69 (2018) 1110-1122].
    J Hepatol. 2019 Jan 4. pii: S0168-8278(18)32522.
    >> Share

  546. DOYLE A, Gorgen A, Muaddi H, Aravinthan AD, et al
    Outcomes of Radiofrequency Ablation as First-Line Therapy for Hepatocellular Carcinoma less than 3 cm in Potentially Transplantable Patients.
    J Hepatol. 2019 Jan 4. pii: S0168-8278(19)30001.
    >> Share

  547. NOBILI V, Schwimmer JB, Vajro P
    Breastfeeding and NAFLD from the maternal side of the mother-infant dyad.
    J Hepatol. 2019;70:13-14.
    >> Share

  548. DIAZ A, Forner A
    Prognosis assessment by pathologist: Is the detection of intratumoural tertiary lymphoid structures a reliable tool?
    J Hepatol. 2019;70:11-12.
    >> Share

    December 2018
  549. MOHKAM K, Mabrut JY
    Reply to: "Treatment for solitary hepatocellular carcinoma ranging from 2 and 5cm: Is the curative effect of no-touch multibipolar radiofrequency ablation comparable to that of surgical resection?"
    J Hepatol. 2018 Dec 24. pii: S0168-8278(18)32579.
    >> Share

  550. TSAY HC, Yuan Q, Balakrishnan A, Kaiser M, et al
    Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis.
    J Hepatol. 2018 Dec 21. pii: S0168-8278(18)32635.
    >> Share

  551. BAUMEISTER SE, Schlesinger S, Aleksandrova K, Jochem C, et al
    Association of Physical Activity and Risk of Hepatobiliary Cancers: A Multinational Cohort Study.
    J Hepatol. 2018 Dec 21. pii: S0168-8278(18)32633.
    >> Share

  552. ZHANG YM, Zhou ZT, Liu GM
    Factors predicting early recurrence after surgical resection of hepatocellular carcinoma.
    J Hepatol. 2018 Dec 19. pii: S0168-8278(18)32523.
    >> Share

  553. CHAN AWH, Berhane S, Cucchetti A, Johnson PJ, et al
    Reply to: Correspondence concerning "Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection".
    J Hepatol. 2018 Dec 18. pii: S0168-8278(18)32577.
    >> Share

  554. DE OLIVEIRA S, Houseright RA, Graves AL, Golenberg N, et al
    Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
    J Hepatol. 2018 Dec 17. pii: S0168-8278(18)32622.
    >> Share

  555. KUSAKABE J, Firl DJ, Sasaki K
    Toward the universal scoring system in treatment for patients with hepatocellular carcinoma.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32508.
    >> Share

  556. ZHANG XY, Ou J, Chen JY, Li WW, et al
    Predicting early hepatocellular carcinoma recurrence after resection: A comment for moving forward.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32491.
    >> Share

  557. RINELLA ME, Trotter JF, Abdelmalek MF, Paredes AH, et al
    Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with nonalcoholic steatohepatitis.
    J Hepatol. 2018 Dec 7. pii: S0168-8278(18)32615.
    >> Share

  558. PARK JW, Kim YJ, Kim DY, Bae SH, et al
    Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: a phase III STAH trial.
    J Hepatol. 2018 Dec 5. pii: S0168-8278(18)32580.
    >> Share

  559. BOEREKAMPS A, Vanwolleghem T, van der Valk M, van den Berk GE, et al
    8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study).
    J Hepatol. 2018 Dec 5. pii: S0168-8278(18)32516.
    >> Share

  560. ICHAI P, Laurent-Bellue A, Camus C, Moreau D, et al
    Liver transplantation in patients with liver failure related to exertional heatstroke.
    J Hepatol. 2018 Dec 3. pii: S0168-8278(18)32575.
    >> Share

    November 2018
  561. STAMM LM, Brainard DM, McHutchison JG
    Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Nov 13. pii: S0168-8278(18)32528.
    >> Share


  562. Reply to: "Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018".
    J Hepatol. 2018 Nov 12. pii: S0168-8278(18)32529.
    >> Share

  563. OTETE H, Deleuran T, Fleming KM, Card T, et al
    Reply to: "Hip fracture risk in patients with alcoholic cirrhosis: Do comorbidities and complications matter?"
    J Hepatol. 2018 Nov 10. pii: S0168-8278(18)32459.
    >> Share

  564. YU SJ, Ma C, Heinrich B, Brown ZJ, et al
    Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    J Hepatol. 2018 Nov 8. pii: S0168-8278(18)32525.
    >> Share

  565. HIRSCHFIELD GM, Chazouilleres O, Drenth JP, Thorburn D, et al
    Effect of NGM282, a FGF19 analogue, in Primary Sclerosing Cholangitis: a Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
    J Hepatol. 2018 Nov 8. pii: S0168-8278(18)32519.
    >> Share

  566. WEISS N, Housset C, Thabut D
    Hepatic encephalopathy: Another brick in the wall.
    J Hepatol. 2018 Nov 7. pii: S0168-8278(18)32499.
    >> Share

  567. ROY A, Taneja S
    Type of organ failure and acute insult have important bearings in outcomes of liver transplantation: A pragmatic discourse.
    J Hepatol. 2018 Nov 3. pii: S0168-8278(18)32384.
    >> Share

  568. THULUVATH PJ, Thuluvath AJ, Hanish S, Savva Y, et al
    Reply to: "Type of organ failure and acute insult have important bearings in outcomes of liver transplantation: A pragmatic discourse".
    J Hepatol. 2018 Nov 2. pii: S0168-8278(18)32496.
    >> Share

  569. FERNANDEZ J, Prado V, Trebicka J, Amoros A, et al
    Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe.
    J Hepatol. 2018 Nov 1. pii: S0168-8278(18)32511.
    >> Share

    October 2018
  570. RAVEN A, Forbes SJ
    Hepatic progenitors in liver regeneration.
    J Hepatol. 2018 Oct 31. pii: S0168-8278(18)30154.
    >> Share

  571. ZHAO LY, Luo YJ, Zhu J, Liu HY, et al
    Hip fracture risk in patients with alcoholic cirrhosis: Do comorbidities and complications matter?
    J Hepatol. 2018 Oct 31. pii: S0168-8278(18)32386.
    >> Share

  572. METWALLY M, Bayoumi A, Romero-Gomez M, Thabet K, et al
    A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR.
    J Hepatol. 2018 Oct 30. pii: S0168-8278(18)32505.
    >> Share

  573. MARASCO G, Colecchia A, Colli A, Ravaioli F, et al
    Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection.
    J Hepatol. 2018 Oct 30. pii: S0168-8278(18)32506.
    >> Share

  574. KIM HY, So YH, Kim W, Ahn DW, et al
    Noninvasive Response Prediction in Prophylactic Carvedilol Therapy for Cirrhotic Patients with Esophageal Varices.
    J Hepatol. 2018 Oct 30. pii: S0168-8278(18)32502.
    >> Share

  575. YIP TC, Wong GL, Chan HL, Tse YK, et al
    HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    J Hepatol. 2018 Oct 24. pii: S0168-8278(18)32497.
    >> Share

  576. IOANNOU GN
    Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment".
    J Hepatol. 2018 Oct 19. pii: S0168-8278(18)32445.
    >> Share

  577. JI F, Yeo YH, He C, Li J, et al
    Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment.
    J Hepatol. 2018 Oct 15. pii: S0168-8278(18)32390.
    >> Share

  578. D'AMICO G, Bataller R
    Need for surveillance of hepatocellular carcinoma in patients with alcoholic cirrhosis.
    J Hepatol. 2018 Oct 11. pii: S0168-8278(18)32447.
    >> Share

  579. O'BRIEN A, Kamath PS, Trotter J
    MACHT - Outpatient albumin infusions do not prevent complications of cirrhosis in patients on the liver transplant waiting list.
    J Hepatol. 2018 Oct 9. pii: S0168-8278(18)32444.
    >> Share

  580. JAYAKUMAR S, Middleton MS, Lawitz EJ, Mantry PS, et al
    Longitudinal Correlations Between MRE, MRI-PDFF, and Liver Histology in Patients with Nonalcoholic Steatohepatitis: Analysis of Data from a Phase 2 Trial of Selonsertib.
    J Hepatol. 2018 Oct 3. pii: S0168-8278(18)32443.
    >> Share

  581. GIANNINI EG, Bodini G, Furnari M, Marabotto E, et al
    NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis.
    J Hepatol. 2018;69:972-973.
    >> Share

  582. DE FRANCHIS R, Krag A
    Ruling out esophageal varices in NAFLD cirrhosis: Can we do without endoscopy?
    J Hepatol. 2018;69:769-771.
    >> Share

  583. CHEN Y, Chen HN, Wang K, Zhang L, et al
    Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma.
    J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32441.
    >> Share

  584. SAGGI H, Maitra D, Jiang A, Zhang R, et al
    Loss of hepatocyte beta-Catenin protects mice from experimental porphyria-associated liver injury.
    J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32442.
    >> Share

    September 2018
  585. DEUGNIER Y, Morcet J, Laine F, Hamdi-Roze H, et al
    Reduced phenotypic expression in genetic hemochromatosis with time: role of exposure to nongenetic modifiers.
    J Hepatol. 2018 Sep 20. pii: S0168-8278(18)32383.
    >> Share

  586. LOW JTS, Rohde G, Pittordou K, Candy B, et al
    Supportive and palliative care in people with cirrhosis: international systematic review of the perspective of patients, family members and health professionals.
    J Hepatol. 2018 Sep 19. pii: S0168-8278(18)32381.
    >> Share

  587. KIM Y, Kang K, Lee SB, Seo D, et al
    Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells.
    J Hepatol. 2018 Sep 18. pii: S0168-8278(18)32380.
    >> Share

  588. FERNANDEZ J, Saliba F
    Liver transplantation in patients with ACLF and multiple organ failure: Time for priority after initial stabilization.
    J Hepatol. 2018 Sep 18. pii: S0168-8278(18)32372.
    >> Share

  589. CHAN AWH, Zhong J, Berhane S, Toyoda H, et al
    Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.
    J Hepatol. 2018 Sep 17. pii: S0168-8278(18)32378.
    >> Share

  590. ZHANG T, Hu J, Wang X, Zhao X, et al
    MicroRNA-378 Promotes Hepatic Inflammation and Fibrosis via Modulation of the NFkappaB-TNFalpha Pathway.
    J Hepatol. 2018 Sep 12. pii: S0168-8278(18)32376.
    >> Share

  591. CALDERARO J, Petitprez F, Becht E, Laurent A, et al
    Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
    J Hepatol. 2018 Sep 10. pii: S0168-8278(18)32373.
    >> Share

  592. TORGERSON PR, Schweiger A, Deplazes P, Pohar M, et al
    Corrigendum to "Alveolar echinococcosis: From a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35years" [J Hepatol 49 (2008) 72-77].
    J Hepatol. 2018 Sep 8. pii: S0168-8278(18)32292.
    >> Share

  593. SHEARER J, Chizhande D, Jones R, Rowe IA, et al
    Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease.
    J Hepatol. 2018 Sep 8. pii: S0168-8278(18)32282.
    >> Share

  594. HADJIHAMBI A, Harrison IF, Costas-Rodriguez M, Vanhaecke F, et al
    Impaired brain glymphatic flow in experimental hepatic encephalopathy.
    J Hepatol. 2018 Sep 7. pii: S0168-8278(18)32367.
    >> Share

  595. GUSTOT T, Moreau R
    Acute-on-Chronic Liver Failure vs. Traditional Acute Decompensation of Cirrhosis.
    J Hepatol. 2018 Sep 6. pii: S0168-8278(18)32370.
    >> Share

  596. PETTA S, Sebastiani G, de Ledinghen V
    Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease".
    J Hepatol. 2018 Sep 4. pii: S0168-8278(18)32300.
    >> Share

  597. GJORGJIEVA M, Calderaro J, Monteillet L, Silva M, et al
    Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia.
    J Hepatol. 2018 Sep 4. pii: S0168-8278(18)32271.
    >> Share

  598. RODRIGUES PM, Perugorria MJ, Santos-Laso A, Bujanda L, et al
    Primary biliary cholangitis: a tale of epigenetically-induced secretory failure?
    J Hepatol. 2018 Sep 4. pii: S0168-8278(18)32362.
    >> Share

  599. MERLI M, Durand F
    Muscle mass vs. adipose tissue to predict outcome in cirrhosis: Which matters and in which patients?
    J Hepatol. 2018;69:567-569.
    >> Share

    August 2018

  600. Corrigendum to "EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis" [J Hepatol 69 (2018) 406-460].
    J Hepatol. 2018 Aug 29. pii: S0168-8278(18)32290.
    >> Share

  601. YOUNOSSI Z, Stepanova M, Sanyal AJ, Harrison SA, et al
    The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options.
    J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32295.
    >> Share

  602. CUBERO FJ, Peng J, Liao L, Su H, et al
    Inactivation of Caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis.
    J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32297.
    >> Share

  603. MOREAU R, Bataller R, Berg T, Lotersztajn S, et al
    Corrigendum to "From the Editor's Desk August 2018" [J Hepatol 69 (2018) 265-268].
    J Hepatol. 2018 Aug 21. pii: S0168-8278(18)32281.
    >> Share

  604. ANDRADE F, Shukla A, Bureau C, Senzolo M, et al
    Pregnancy in Idiopathic Non-Cirrhotic Portal Hypertension: A Multicentric Study on Maternal and Fetal Management and Outcome.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32286.
    >> Share

  605. CLARK VC, Marek G, Liu C, Collinsworth A, et al
    Clinical and Histologic Features of Adults with Alpha-1 Antitrypsin Deficiency in a Non-Cirrhotic Cohort.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32284.
    >> Share

  606. IOANNOU GN, Green PK, Beste LA, Mun EJ, et al
    Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32287.
    >> Share

  607. SOLA E, Sole C, Simon-Talero M, Martin-Llahi M, et al
    MIDODRINE &ALBUMIN for Preventing COMPLICATIONS IN PATIENTS WITH CIRRHOSIS AWAITING Liver transplantation.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32285.
    >> Share

  608. FONTANA RJ, Cirulli ET, Gu J, Kleiner D, et al
    The role of HLA-A *33:01 in Patients with Cholestatic Hepatitis attributed to Terbinafine.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32283.
    >> Share

  609. BRUIX J, Cheng AL, Meinhardt G, Nakajima K, et al
    Corrigendum to "Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies" [J hepatol 67 (2017) 999-1008].
    J Hepatol. 2018 Aug 10. pii: S0168-8278(18)32269.
    >> Share

  610. ASRANI SK, Saracino G, O'Leary JG, Gonzalez S, et al
    Corrigendum to "Recipient characteristics and morbidity and mortality after liver transplantation" [J hepatol 69 (2018) 43-50].
    J Hepatol. 2018 Aug 7. pii: S0168-8278(18)32268.
    >> Share

  611. YANG X, Chen J, Wang N, Liu Z, et al
    Clinical use of dendritic cell-derived exosomes for hepatocellular carcinoma immunotherapy: How far we are?
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32183.
    >> Share

  612. GANNE-CARRIE N, Chaffaut C, Bourcier V, Archambeaud I, et al
    Estimate of hepatocellular carcinoma's incidence in patients with alcoholic cirrhosis.
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32278.
    >> Share

  613. TSUCHIDA T, Lee YA, Fujiwara N, Ybanez M, et al
    Corrigendum to "A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer" [J Hepatol 69 (2018) 385-395].
    J Hepatol. 2018 Aug 3. pii: S0168-8278(18)32263.
    >> Share

    July 2018
  614. KIM JH, Kim YD, Lee M, Jun BG, et al
    Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
    J Hepatol. 2018 Jul 31. pii: S0168-8278(18)32274.
    >> Share

  615. MAROT A, Henrion J, Knebel JF, Deltenre P, et al
    Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis.
    J Hepatol. 2018 Jul 23. pii: S0168-8278(18)32160.
    >> Share

  616. LAUTERIO A, Moioli MC, Di Sandro S, Travi G, et al
    HIV-positive to HIV-positive liver transplantation: To be continued.
    J Hepatol. 2018 Jul 23. pii: S0168-8278(18)32180.
    >> Share

  617. AJI T, Dong JH, Shao YM, Zhao JM, et al
    Ex vivo Liver Resection and Autotransplantation as Alternative to Allotransplantation for End-stage Hepatic Alveolar Echinococcosis.
    J Hepatol. 2018 Jul 19. pii: S0168-8278(18)32258.
    >> Share

  618. SCOTT CL, Guilliams M
    The role of Kupffer cells in hepatic iron and lipid metabolism.
    J Hepatol. 2018 Jul 9. pii: S0168-8278(18)30130.
    >> Share

  619. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Reply to: "NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis": Cryptogenic cirrhosis should not be equated with NASH cirrhosis based on UNOS data mining and Bayesian 'doctrine of chances'.
    J Hepatol. 2018 Jul 5. pii: S0168-8278(18)32168.
    >> Share

  620. PLOTON M, Mazuy C, Gheeraert C, Dubois V, et al
    The Nuclear Bile Acid Receptor FXR is a PKA- and FOXA2-Sensitive Activator of Fasting Hepatic Gluconeogenesis.
    J Hepatol. 2018 Jul 4. pii: S0168-8278(18)32175.
    >> Share

  621. LAI SW, Lin CL, Liao KF
    Association between cirrhosis and hip fracture in older people in a population-based cohort study.
    J Hepatol. 2018 Jul 2. pii: S0168-8278(18)32060.
    >> Share

    June 2018
  622. HUTCHINSON JA, Schlitt HJ
    Subclinical T cell-mediated liver transplant rejection: The jury is still out.
    J Hepatol. 2018 Jun 30. pii: S0168-8278(18)32157.
    >> Share

  623. TANDON P, Ismond KP, Riess K, Duarte-Rojo A, et al
    Exercise in Cirrhosis: Translating evidence and experience to practice.
    J Hepatol. 2018 Jun 28. pii: S0168-8278(18)32170.
    >> Share

  624. FUHRMANN V, Krowka M
    Hepatopulmonary syndrome.
    J Hepatol. 2018 Jun 27. pii: S0168-8278(18)30007.
    >> Share

  625. QIN JJ, Mao W, Wang X, Sun P, et al
    Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1.
    J Hepatol. 2018 Jun 26. pii: S0168-8278(18)32167.
    >> Share

  626. YU JJ, Li JD, Xu XF, Shen F, et al
    Is obesity a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis?
    J Hepatol. 2018 Jun 8. pii: S0168-8278(18)32061.
    >> Share

  627. BRADLEY CR, Cox EF, Scott RA, James MW, et al
    Multi organ assessment of Compensated Cirrhosis Patients using quantitative Magnetic Resonance Imaging.
    J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32122.
    >> Share

  628. TONG M, Che N, Zhou L, Luk ST, et al
    Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    J Hepatol. 2018 Jun 6. pii: S0168-8278(18)32119.
    >> Share

  629. SEGERITZ CP, Rashid ST, Cardoso de Brito M, Paola MS, et al
    hiPSC hepatocyte model demonstrates the role of unfolded protein response and inflammatory networks in alpha1-antitrypsin deficiency.
    J Hepatol. 2018 Jun 4. pii: S0168-8278(18)32113.
    >> Share

  630. TURCO L, Garcia-Tsao G, Rossi R, Villa E, et al
    Reply to "The Relationship of Hyperdynamic Circulation and Cardiodynamic States in Cirrhosis".
    J Hepatol. 2018 Jun 2. pii: S0168-8278(18)32101.
    >> Share

  631. NAKAMURA K, Zhang M, Kageyama S, Ke B, et al
    Protective effects of heme oxygenase 1 during ischemia r epefrfsuion injury: Hepatocytes or non parenchymal cells?
    J Hepatol. 2018 Jun 2. pii: S0168-8278(18)32114.
    >> Share

  632. LEE S, Kang TW
    Reply to "Influence of ablation technique on treatment failure for perivascular hepatocellular carcinoma".
    J Hepatol. 2018 Jun 2. pii: S0168-8278(18)32117.
    >> Share

    May 2018
  633. SUNDARAM V, Goldberg DS, Jalan R
    Author response: Is obesity a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis?
    J Hepatol. 2018 May 31. pii: S0168-8278(18)32100.
    >> Share

  634. MOHKAM K, Rode A, Mabrut JY
    Influence of ablation technique on treatment failure for perivascular hepatocellular carcinoma.
    J Hepatol. 2018 May 25. pii: S0168-8278(18)32045.
    >> Share

  635. PETTA S, Sebastiani G, Bugianesi E, Vigano M, et al
    Noninvasive Prediction of Esophageal Varices by Stiffness and Platelet in Nonalcoholic Fatty Liver Disease Cirrhosis.
    J Hepatol. 2018 May 23. pii: S0168-8278(18)32065.
    >> Share

  636. LE GUILCHER C, Garcin I, Dellis O, Cauchois F, et al
    The P2X4 purinergic receptor regulates hepatic myofibroblast activation during liver fibrogenesis.
    J Hepatol. 2018 May 23. pii: S0168-8278(18)32066.
    >> Share

  637. GUICCIARDI ME, Trussoni CE, Krishnan A, Bronk SF, et al
    Macrophages Contribute to the Pathogenesis of Sclerosing Cholangitis in Mice.
    J Hepatol. 2018 May 23. pii: S0168-8278(18)32064.
    >> Share

  638. ALVARADO E, Garcia-Guix M, Mirabet S, Villanueva C, et al
    The relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis.
    J Hepatol. 2018 May 18. pii: S0168-8278(18)32044.
    >> Share

  639. XU D, Xu M, Kong X, Xia Q, et al
    Protective effects of heme oxygenase 1 during ischemia-reperfusion injury: Hepatocytes or non-parenchymal cells?
    J Hepatol. 2018 May 17. pii: S0168-8278(18)32046.
    >> Share

  640. NOORDZIJ W, de Jong KP, de Meijer VE
    Response to: Positron emission tomography/computed tomography with (18)F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
    J Hepatol. 2018 May 17. pii: S0168-8278(18)32024.
    >> Share

  641. BANERJEE R, Kelly M, Wilman H, Wright T, et al
    Imaging endpoints for non-alcoholic steatohepatitis (NASH) therapeutic trials: A growing role for multiparametric MRI?
    J Hepatol. 2018 May 16. pii: S0168-8278(18)32033.
    >> Share

  642. SUAREZ-AMARAN L, Usai C, Di Scala M, Godoy C, et al
    Erratum to "A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-beta induction" [J Hepatol 67 (2017) 669-679].
    J Hepatol. 2018 May 15. pii: S0168-8278(18)32010.
    >> Share

  643. PATNAIK MM, Kamath PS, Simonetto DA
    Grand Rounds: Hepatic Manifestations of Telomere Biology Disorders.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32052.
    >> Share

  644. WONG GL, Chan HL, Tse YK, Yip TC, et al
    Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32055.
    >> Share

  645. ORRU C, Szydlowska M, Taguchi K, Zavattari P, et al
    Genetic inactivation of Nrf2 prevents clonal expansion of initiated cells in a nutritional model of rat hepatocarcinogenesis.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32056.
    >> Share

  646. OH SH, Swiderska-Syn M, Jewell ML, Premont RT, et al
    Liver regeneration requires Yap1-TGFbeta-dependent epithelial-mesenchymal transition in hepatocytes.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32054.
    >> Share

    April 2018
  647. CHALAYE J, Costentin CE, Luciani A, Nault JC, et al
    Reply to "PET/CT with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma".
    J Hepatol. 2018 Apr 29. pii: S0168-8278(18)32031.
    >> Share

  648. MOLLER S, Lee SS
    Cirrhotic cardiomyopathy.
    J Hepatol. 2018 Apr 28. pii: S0168-8278(18)30017.
    >> Share

  649. EBADI M, Tandon P, Moctezuma-Velazquez C, Ghosh S, et al
    Low Subcutaneous Adiposity Associates with Higher Mortality in Female Patients with Cirrhosis.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32026.
    >> Share

  650. SUNDARAM V, Jalan R, Ahn JC, Charlton MR, et al
    Class III obesity is a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32027.
    >> Share

  651. ZHAO L, Zhang C, Luo X, Wang P, et al
    CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.
    J Hepatol. 2018 Apr 26. pii: S0168-8278(18)32014.
    >> Share

  652. SPOSITO C, Spreafico C, Mazzaferro V
    Re: validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    J Hepatol. 2018 Apr 26. pii: S0168-8278(18)32016.
    >> Share

  653. OTETE H, Deleuran T, Fleming KM, Card TR, et al
    Hip fracture risk in patients with alcoholic cirrhosis: a population-based study using English and Danish data.
    J Hepatol. 2018 Apr 16. pii: S0168-8278(18)31978.
    >> Share

  654. WIEST R, Albillos A, Trauner M, Bajaj JS, et al
    Corrigendum to "Targeting the gut-liver axis in liver disease" [J Hepatol 67 (2017) 1084-1103].
    J Hepatol. 2018 Apr 11. pii: S0168-8278(18)30149.
    >> Share


  655. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.
    J Hepatol. 2018 Apr 10. pii: S0168-8278(18)31966.
    >> Share


  656. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.
    J Hepatol. 2018 Apr 5. pii: S0168-8278(18)30215.
    >> Share

  657. LUCIDI C, Lattanzi B, Riggio O, Merli M, et al
    May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?
    J Hepatol. 2018 Apr 4. pii: S0168-8278(18)30213.
    >> Share

  658. VAN VUGT JLA, Alferink LJM, Buettner S, Metselaar HJ, et al
    Reply to: "May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?" and "Has the time come for using MELD-Sarcopenia score?"
    J Hepatol. 2018 Apr 3. pii: S0168-8278(18)30212.
    >> Share

  659. BAJAJ JS
    Hepatic encephalopathy: classification and treatment.
    J Hepatol. 2018;68:838-839.
    >> Share

  660. BEIER JI, Banales JM
    Pyroptosis: An inflammatory link between NAFLD and NASH with potential therapeutic implications.
    J Hepatol. 2018;68:643-645.
    >> Share

  661. LEE S, Kim SH
    Reply to: "Detecting microvascular invasion in HCC with contrast-enhanced MRI: Is it a good idea?"
    J Hepatol. 2018;68:863-864.
    >> Share

  662. HUO TI, Liu PH, Hsu CY
    Detecting microvascular invasion in HCC with contrast-enhanced MRI: Is it a good idea?
    J Hepatol. 2018;68:862-863.
    >> Share

  663. ATKINSON SR, Way MJ, McQuillin A, Morgan MY, et al
    Reply to: "The PNPLA3 SNP rs738409:G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort".
    J Hepatol. 2018;68:860-862.
    >> Share

  664. BYRNE CD, Perseghin G
    Non-alcoholic fatty liver disease: A risk factor for myocardial dysfunction?
    J Hepatol. 2018;68:640-642.
    >> Share

  665. MENDIZABAL M, Silva M
    Acute liver failure: Do the EASL guidelines address the whole spectrum?
    J Hepatol. 2018;68:843.
    >> Share

    March 2018
  666. TSUCHIDA T, Lee YA, Fujiwara N, Ybanez M, et al
    A Simple Diet- and Chemical-Induced Murine NASH Model with Rapid Progression of Steatohepatitis, Fibrosis and Liver Cancer.
    J Hepatol. 2018 Mar 20. pii: S0168-8278(18)30175.
    >> Share

  667. TURNER AM, Stolk J, Bals R, Lickliter J, et al
    Hepatic-targeted RNA interference provides persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.
    J Hepatol. 2018 Mar 20. pii: S0168-8278(18)30176.
    >> Share

  668. KONERMAN MA, Jones JC, Harrison SA
    Corrigendum to "Pharmacotherapy for NASH: Current and emerging" [J Hepatol 68 (2017) 362-375].
    J Hepatol. 2018 Mar 19. pii: S0168-8278(18)30150.
    >> Share

  669. PEREYRA D, Starlinger P
    Intra Platelet Serotonin Affects Overall Survival in Hepatocellular Cancer Patients.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30166.
    >> Share

  670. HSU YC, Cheuk-Fung Yip T, Ho HJ, Wai-Sun Wong V, et al
    Development of a scoring system to Predict Hepatocellular Carcinoma in Asians on Antivirals for Chronic Hepatitis B.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30170.
    >> Share

  671. ROMANO A, Angeli P, Piovesan S, Noventa F, et al
    "Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study".
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30172.
    >> Share

  672. PUOTI M, Foster GR, Wang S, Mutimer D, et al
    High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30165.
    >> Share

  673. DONG LQ, Shi Y, Ma LJ, Yang LX, et al
    Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30167.
    >> Share

  674. MOSCONI C, Cucchetti A, Pettinato C, Golfieri R, et al
    Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    J Hepatol. 2018 Mar 13. pii: S0168-8278(18)30151.
    >> Share

  675. ABITBOL S, Dahmani R, Coulouarn C, Ragazzon B, et al
    AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of beta-catenin activation.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(17)32534.
    >> Share

  676. LEE S, Kang TW, Cha DI, Song KD, et al
    Radiofrequency ablation versus surgery for perivascular hepatocellular carcinoma: propensity score analyses of long-term outcomes.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30148.
    >> Share

  677. ZHANG Z, Filzmayer C, Ni Y, Sultmann H, et al
    Hepatitis D Virus replication is sensed by MDA5 and induces IFN-beta/lambda responses in hepatocytes.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30143.
    >> Share

  678. CHALAYE J, Costentin CE, Luciani A, Amaddeo G, et al
    Positron emission tomography / computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
    J Hepatol. 2018 Mar 5. pii: S0168-8278(18)30136.
    >> Share

  679. LIU JJ, Li Y, Chen WS, Liang Y, et al
    Shp2 Deletion in Hepatocytes Suppresses Hepatocarcinogenesis Driven by Oncogenic beta-Catenin, PIK3CA and MET.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30131.
    >> Share

  680. NAULT JC, Galle PR, Marquardt JU
    The role of molecular enrichment on future therapies in hepatocellular carcinoma.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30134.
    >> Share

  681. KARLSEN TH, Tacke F
    <<The times they are a'changin'>> - Positioning the European Association for the Study of the Liver in the changing landscape of hepatology.
    J Hepatol. 2018 Mar 1. pii: S0168-8278(18)30112.
    >> Share

  682. LOUVET A, Krag A
    Managing excessive alcohol consumption at a population level: The earlier the better.
    J Hepatol. 2018;68:389-390.
    >> Share

  683. NAGATA H, Nakagawa M, Asahina Y
    Reply to: "Imaging Basis of AFP and WFA(+)M2BP as Indicators of the risk of HCC after SVR".
    J Hepatol. 2018;68:607-608.
    >> Share

  684. MAZZEO AT, Maimone S
    Acid-base disorders in liver disease.
    J Hepatol. 2018;68:617-618.
    >> Share

  685. SCHEINER B, Funk GC
    Reply to: "Acid-base disorders in liver disease".
    J Hepatol. 2018;68:618-619.
    >> Share

  686. WAZIRY R, Amin J, Law M, Dore GJ, et al
    Reply to: "Direct antiviral agents and risk of HCC: Waiting for Godot".
    J Hepatol. 2018;68:616-617.
    >> Share

  687. WANG XC, Zhang XY, Zhang X, Yuan ZX, et al
    Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM(VCTE) algorithm.
    J Hepatol. 2018;68:602-603.
    >> Share

  688. PETIT JM, Bouillet B, Loffroy R, Rouland A, et al
    Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes.
    J Hepatol. 2018;68:603-604.
    >> Share

  689. BOURSIER J, de Ledinghen V, Leroy V, Cales P, et al
    Reply to: "Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM(VCTE) algorithm" and to "Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes".
    J Hepatol. 2018;68:605-606.
    >> Share

  690. GALAND J, Ley D, Coopman S, Michaud L, et al
    Primary prophylaxis of oesophageal variceal bleeding in children by ligation is safe and as efficient as secondary prophylaxis.
    J Hepatol. 2018;68:600-601.
    >> Share

    February 2018
  691. SHA M, Jeong S, Xia Q
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection: Novel Concerns.
    J Hepatol. 2018 Feb 20. pii: S0168-8278(18)30122.
    >> Share

  692. LYU N, Kong Y, Mu L, Lin Y, et al
    Hepatic Arterial Infusion of Oxaliplatin plus Fluorouracil/Leucovorin versus Sorafenib for Advanced Hepatocellular Carcinoma.
    J Hepatol. 2018 Feb 19. pii: S0168-8278(18)30125.
    >> Share

  693. LI J, Lei Z, Wang K, Shen F, et al
    Reply to "Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: novel concerns".
    J Hepatol. 2018 Feb 17. pii: S0168-8278(18)30127.
    >> Share

  694. COENRAAD MJ, Porcher R, Bendtsen F
    Hepatic and cardiac hemodynamics and systemic inflammation in cirrhosis: it takes three to tango.
    J Hepatol. 2018 Feb 17. pii: S0168-8278(18)30124.
    >> Share

  695. NISHIZAWA N, Ito Y, Eshima K, Ohkubo H, et al
    Inhibition of microsomal prostaglandin E synthase-1 facilitates liver repair after hepatic injury in mice.
    J Hepatol. 2018 Feb 16. pii: S0168-8278(18)30126.
    >> Share

  696. DUAN F, Wu H, Jia D, Wu W, et al
    O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis.
    J Hepatol. 2018 Feb 14. pii: S0168-8278(18)30119.
    >> Share

  697. ASRANI SK, Saracino G, O'Leary JG, Gonzales S, et al
    Recipient characteristics and morbidity and mortality after liver transplantation.
    J Hepatol. 2018 Feb 14. pii: S0168-8278(18)30120.
    >> Share

  698. ZHANG P, Ge Z, Wang H, Feng W, et al
    Prolactin improves hepatic steatosis via CD36 pathway.
    J Hepatol. 2018 Feb 13. pii: S0168-8278(18)30115.
    >> Share

  699. YOON YI, Song GW, Lee SG, Hwang S, et al
    Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.
    J Hepatol. 2018 Feb 13. pii: S0168-8278(18)30113.
    >> Share

  700. GUIU B, Jouve JL, Schmitt A, Minello A, et al
    Intra-arterial Idarubicin_lipiodol without embolization in hepatocellular carcinoma: the LIDA-B phase I trial.
    J Hepatol. 2018 Feb 7. pii: S0168-8278(18)30069.
    >> Share

  701. KIM AY, Sinn DH, Jeong WK, Kim YK, et al
    Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma.
    J Hepatol. 2018 Feb 2. pii: S0168-8278(18)30071.
    >> Share

  702. MOHKAM K, Dumont PN, Manichon AF, Jouvet JC, et al
    No touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm.
    J Hepatol. 2018 Feb 1. pii: S0168-8278(18)30057.
    >> Share

  703. LIM C, Salloum C, Azoulay D
    Reply to Letter: "Liver resection for BCLC 0-A stage hepatocellular carcinoma: does the time to surgery not impact the prognosis".
    J Hepatol. 2018 Feb 1. pii: S0168-8278(18)30067.
    >> Share

    January 2018
  704. PEI Y, Chen X, Zhang W
    Liver resection for BCLC 0-A stage hepatocellular carcinoma: does the time to surgery not impact the prognosis?
    J Hepatol. 2018 Jan 31. pii: S0168-8278(18)30065.
    >> Share

  705. BUREAU C, Adebayo D, de Rieu MC, Elkrief L, et al
    Corrigendum to "Alfapump(R) system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study" [J Hepatol 67 (2017) 940-949].
    J Hepatol. 2018 Jan 29. pii: S0168-8278(17)32532.
    >> Share

  706. YU J, Xu QG, Wang ZG, Yang Y, et al
    Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma.
    J Hepatol. 2018 Jan 26. pii: S0168-8278(18)30055.
    >> Share

  707. GEHRKE N, Hovelmeyer N, Waisman A, Straub BK, et al
    Hepatocyte-specific deletion of IL1-RI attenuatesliver injury by blocking IL-1 driven autoinflammation.
    J Hepatol. 2018 Jan 20. pii: S0168-8278(18)30020.
    >> Share

  708. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Corrigendum to "Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV" [J Hepatol 68 (2018) 33-41].
    J Hepatol. 2018 Jan 20. pii: S0168-8278(18)30013.
    >> Share

  709. THIELE M, Rausch V, Fluhr G, Kjaergaard M, et al
    Controlled Attenuation Parameter And Alcoholic Hepatic Steatosis: Diagnostic Accuracy and Role Of Alcohol Detoxification.
    J Hepatol. 2018 Jan 14. pii: S0168-8278(18)30016.
    >> Share

  710. SPREAFICO C, Sposito C, Vaiani M, Cascella T, et al
    Development of a prognostic score to predict response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30010.
    >> Share

  711. ORCI LA, Lacotte S, Delaune V, Slits F, et al
    Effects of the gut-liver axis on ischemia-mediated hepatocellular carcinoma recurrence in the mouse liver.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30009.
    >> Share

  712. LEVADA K, Guldiken N, Zhang X, Vella G, et al
    Hsp72 protects from liver injury via attenuation of hepatocellular death, oxidative stress and JNK-signaling.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30008.
    >> Share

  713. TURCO L, Garcia-Tsao G, Magnani I, Bianchini M, et al
    Cardiopulmonary hemodynamics and c-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30011.
    >> Share

  714. THOMAS JA, Ramachandran P, Forbes SJ
    Studies of macrophage therapy for cirrhosis - from mice to men.
    J Hepatol. 2018 Jan 6. pii: S0168-8278(18)30002.
    >> Share

    December 2017
  715. UTOH R, Komori J, Kuge H, Tatsumi K, et al
    Adult hepatocytes direct liver organogenesis through non-parenchymal cell recruitment in the kidney.
    J Hepatol. 2017 Dec 26. pii: S0168-8278(17)32531.
    >> Share

  716. XU B, Jiang M, Chu Y, Wang W, et al
    Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    J Hepatol. 2017 Dec 19. pii: S0168-8278(17)32494.
    >> Share

  717. LI L, Barry V, Daffis S, Niu C, et al
    Anti-HBV Response to Toll-Like Receptor 7 Agonist GS-9620 is Associated with Intrahepatic Aggregates of T Cells and B Cells.
    J Hepatol. 2017 Dec 14. pii: S0168-8278(17)32490.
    >> Share

  718. CALDWELL S, Marchesini G
    Cryptogenic vs NASH-cirrhosis: The rose exists well before its name.
    J Hepatol. 2017 Dec 13. pii: S0168-8278(17)32488.
    >> Share

  719. OVREHUS ALH, Krarup H, Birkemose I, Holm DK, et al
    Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32475.
    >> Share

  720. RATZIU V
    A critical review of endpoints for non-cirrhotic NASH therapeutic trials.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32481.
    >> Share

  721. VAN VUGT JLA, Alferink LJM, Buettner S, Gaspersz MP, et al
    A Model including Sarcopenia Surpasses the MELD Score in Predicting Waiting List Mortality in Cirrhotic Liver Transplant Candidates.
    J Hepatol. 2017 Dec 5. pii: S0168-8278(17)32474.
    >> Share

    November 2017
  722. LAU HH, Ng NHJ, Loo LSW, Jasmen J, et al
    The molecular functions of hepatocyte nuclear factors in and beyond the liver.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32451.
    >> Share

  723. LEE YH, Kim KJ, Yoo ME, Kim G, et al
    Association of nonalcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32448.
    >> Share

  724. NOBILI V, Mosca A, Scorletti E, Byrne CD, et al
    Reply 'Energy drinks and risk of non alcoholic steatohepatitis'.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32446.
    >> Share

  725. ROBIN S, Buchanan R, Poole R
    Energy drinks and adolescents - a hepatic health hazard?
    J Hepatol. 2017 Nov 22. pii: S0168-8278(17)32444.
    >> Share

  726. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Is Cryptogenic Cirrhosis Different from NASH Cirrhosis?
    J Hepatol. 2017 Nov 18. pii: S0168-8278(17)32441.
    >> Share

  727. LEI Z, Xia Y, Si A, Wang K, et al
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection.
    J Hepatol. 2017 Nov 16. pii: S0168-8278(17)32438.
    >> Share

  728. INNES H, Barclay ST, Hayes PC, Fraser A, et al
    The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429.
    >> Share

  729. SCHLEGEL A, Kalisvaart M, Scalera I, Laing RW, et al
    The UK-DCD-Risk-Score: a new proposal to define futility in Donation after Circulatory Death liver transplantation.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32432.
    >> Share

  730. TERZI E, Iavarone M, Pompili M, Veronese L, et al
    Contrast enhanced ultrasound identifies hepatocellular carcinoma in cirrhosis: a large multicenter retrospective study.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32428.
    >> Share

  731. LINECKER M, Krones T, Berg T, Niemann CU, et al
    Potentially Inappropriate Liver Transplantation in the Era of the "Sickest-first" Policy - A Search for the Upper Limits.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32430.
    >> Share

  732. HU C, Li W, Tian F, Jiang K, et al
    Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
    J Hepatol. 2017 Nov 4. pii: S0168-8278(17)32409.
    >> Share

  733. HAYES P, Mookerjee RP
    Early TIPS for portal hypertensive related bleeding: Is resource or education the reason for failure to show clear survival benefit?
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32410.
    >> Share

    October 2017
  734. MOHAMMED MS, Ferrier G, Abouda G, Corless L, et al
    Socio-economic deprivation significantly impacts clinical management and survival in hepatocellular carcinoma.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32403.
    >> Share

  735. ASHHAB AA, Rodin H, Debes JD
    Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors don't seem to matter, unless you are an immigrant-Authors-reply.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32404.
    >> Share

  736. CHOUDHARY NS, Saraf N, Soin AS
    Liver Transplantation for Grade 3 Acute on Chronic Liver Failure: Type of Organ Failure is Important.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32401.
    >> Share

  737. ARTRU F, Louvet A
    Reply to <<Liver transplantation for grade 3 acute-on-chronic liver failure: type of organ failure is important>>.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32402.
    >> Share

  738. D'AMICO G, Morabito A, D'Amico M, Pasta L, et al
    Clinical states of cirrhosis and competing risks.
    J Hepatol. 2017 Oct 27. pii: S0168-8278(17)32399.
    >> Share

  739. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32398.
    >> Share

  740. KIM G, Jang SY, Nam CM, Kang ES, et al
    Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32397.
    >> Share

  741. KIM KM, Han CY, Kim JY, Cho SS, et al
    Galpha12 overexpression induced by miR16 dysregulation contributes to liver fibrosis by promoting autophagy in hepatic stellate cells.
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32388.
    >> Share

  742. JACKSON R, Psarelli EE, Berhane S, Johnson PJ, et al
    Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32389.
    >> Share

  743. BRUIX J, Cheng AL, Llovet J
    Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32392.
    >> Share

  744. NAULT JC, Sutter O, Nahon P, Ganne-Carrie N, et al
    Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations.
    J Hepatol. 2017 Oct 12. pii: S0168-8278(17)32351.
    >> Share

  745. YU Y, Wang J, Li G, Shen C, et al
    Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?
    J Hepatol. 2017 Oct 6. pii: S0168-8278(17)32346.
    >> Share

  746. FUJIWARA N, Friedman SL, Goossens N, Hoshida Y, et al
    Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.
    J Hepatol. 2017 Oct 5. pii: S0168-8278(17)32328.
    >> Share

  747. LIM C, Bhangui P, Salloum C, Gavara CG, et al
    Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma.
    J Hepatol. 2017 Oct 5. pii: S0168-8278(17)32331.
    >> Share

  748. GUSTOT T, Agarwal B
    Selected patients with acute-on-chronic liver failure grade 3 are not too sick to be considered for liver transplantation.
    J Hepatol. 2017;67:667-668.
    >> Share

    September 2017
  749. VERHOEVEN CJ, Selten JW, Roest HP, Farid WRR, et al
    Corrigendum to "MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation" [J Hepatol 2013; 59:1231-1238].
    J Hepatol. 2017 Sep 27. pii: S0168-8278(17)32279.
    >> Share

  750. GANDHI CR
    Hepatic stellate cell activation and pro-fibrogenic signals.
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32068.
    >> Share

  751. BESTE LA, Green PK, Berry K, Kogut MJ, et al
    Reply to Letters to the Editor from Mazzarelli et al. entitled "Direct-acting antiviral therapy in patients with hepatocellular cancer: the timing of treatment is everything" and Tammineedi et al. entitled "More extended indication of DAA therapy in p
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32292.
    >> Share

  752. THABUT D, Pauwels A, Carbonell N, Remy AJ, et al
    Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results.
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32281.
    >> Share

  753. PRENNER S, Kulik L
    Reply to "Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma".
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32283.
    >> Share

  754. HUANG A, Zhao X, Yang XR, Li FQ, et al
    Corrigendum to "Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma" [J Hepatol 67 (2017) 293-301].
    J Hepatol. 2017 Sep 12. pii: S0168-8278(17)32207.
    >> Share

  755. MOOKERJEE RP, Mehta G, Balasubramaniyan V, Mohamed FEZ, et al
    Corrigendum to "Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension" [J Hepatol 62 (2015) 325-331].
    J Hepatol. 2017 Sep 8. pii: S0168-8278(17)32209.
    >> Share

  756. FANGAZIO S, Camatta D, Minh MT, Ceriani E, et al
    Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma.
    J Hepatol. 2017 Sep 7. pii: S0168-8278(17)32280.
    >> Share

  757. IOANNOU GN, Green PK, Berry K
    HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32273.
    >> Share

  758. WANG X, Mao W, Fang C, Tian S, et al
    Dusp14 protects against hepatic ischemia-reperfusion injury via Tak1 suppression.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32275.
    >> Share

  759. QI X, Liu F, Li Z, Chen S, et al
    Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32277.
    >> Share

  760. IRANMANESH P, Toso C
    Reply to the Letter to the Editor by Qi et al. entitled "Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis".
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32274.
    >> Share

  761. URBAN SK, Krawczyk M, Willms A, Sanger H, et al
    Diagnostic and Prognostic Role of Circulating Microparticles in Hepatocellular Carcinoma.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32262.
    >> Share

  762. MAZZARELLI C, Cannon MD, Belli LS, Agarwal K, et al
    Direct-acting antiviral therapy in patients with hepatocellular cancer: the timing of treatment is everything.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32265.
    >> Share

  763. HUANG R, Liu Y, Wang J, Xia J, et al
    Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32270.
    >> Share

  764. WANG J, Yu Y, Li G, Shen C, et al
    Relationship between serum HBV RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32261.
    >> Share

  765. WANG M, Shen G, Xu L, Liu X, et al
    IL-1 receptor like 1 protects against alcoholic liver injury by limiting NF-kappaB activation in hepatic macrophages.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32263.
    >> Share

  766. YIP TC, Chan HL, Wong VW, Wong GL, et al
    Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance".
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32266.
    >> Share

  767. PONZIANI FR, Giarretta I, Nicoletti A, Gatto I, et al
    Diagnostic and Prognostic Role of Circulating Microparticles in Hepatocellular Carcinoma.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32257.
    >> Share

  768. GROSSI G, Loglio A, Facchetti F, Borghi M, et al
    Tenofovir alafenamide as a Rescue Therapy in a Cirrhotic HBV Patient with a Hystory of Fanconi Syndrome and Multidrug Resistance: A Case Report.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32260.
    >> Share

    August 2017
  769. SHARMA SA, Kowgier M, Hansen BE, Pieter Brouwer W, et al
    Toronto HCC Risk Index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.
    J Hepatol. 2017 Aug 24. pii: S0168-8278(17)32248.
    >> Share

  770. TORRECILLA S, Sia D, Harrington AN, Zhang Z, et al
    Trunk events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32252.
    >> Share

  771. CHIANG DY, Villanueva A
    Progress towards molecular patient stratification of hepatocellular carcinoma: lost in translation?
    J Hepatol. 2017 Aug 21. pii: S0168-8278(17)32210.
    >> Share

  772. PETTA S, Marchesini G
    Corrigendum to "Coffee and tea breaks for liver health" [J Hepatol 67 (2017) 221-223].
    J Hepatol. 2017 Aug 16. pii: S0168-8278(17)32186.
    >> Share

  773. REBOUISSOU S, Zucman-Rossi J, Moreau R, Qiu Z, et al
    Note of caution: contaminations of hepatocellular cell lines.
    J Hepatol. 2017 Aug 11. pii: S0168-8278(17)32206.
    >> Share

  774. DONATO MF, Invernizzi F, Rossi G, Iavarone M, et al
    Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32200.
    >> Share

  775. MAJUMDAR A, Bailey M, Kemp WM, Bellomo R, et al
    Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32198.
    >> Share

  776. WAZIRY R, Hajarizadeh B, Grebely J, Amin J, et al
    Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32199.
    >> Share

  777. DONG YANG J, Leise MD
    Reply to " Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence".
    J Hepatol. 2017 Aug 8. pii: S0168-8278(17)32201.
    >> Share

  778. SEBASTIAN M, Johannes M
    Is Room Temperature Susceptometry really an accurate method to assess hepatocellular iron? A response.
    J Hepatol. 2017 Aug 7. pii: S0168-8278(17)32192.
    >> Share

  779. PAISANT A, Laine F, Gandon Y, Bardou-Jacquet E, et al
    Is Room Temperature Susceptometer really an accurate method to assess hepatocellular iron?
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32193.
    >> Share

  780. THALHEIMER U, Giannelli V, Maimone S
    Non selective beta blockers in cirrhosis.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32194.
    >> Share

  781. DEZSO K, Rokusz A, Bugyik E, Szucs A, et al
    Erratum to "Human liver regeneration in advanced cirrhosis is organized by the portal tree" [J Hepatol 66 (2017) 778-786].
    J Hepatol. 2017;67:430-436.
    >> Share

    July 2017
  782. LEE S, Kim SH
    Reply to: "How to Better Predict Microvascular Invasion and Recurrence of Hepatocellular Carcinoma".
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32156.
    >> Share

  783. XU XF, Yu JJ, Xing H, Shen F, et al
    How to Better Predict Microvascular Invasion and Recurrence of Hepatocellular Carcinoma.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32157.
    >> Share

  784. BERG T, Simon KG, Mauss S, Schott E, et al
    Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32155.
    >> Share

  785. LEE WM
    Public Health: Acetaminophen (APAP) Hepatotoxicity- Isn't It Time for APAP to Go Away?
    J Hepatol. 2017 Jul 19. pii: S0168-8278(17)32148.
    >> Share

  786. NAULT JC, Paradis V, Cherqui D, Vilgrain V, et al
    Molecular classification of hepatocellular adenoma in clinical practice.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32152.
    >> Share

  787. PIANO S, Tonon M, Vettore E, Stanco M, et al
    Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32151.
    >> Share

  788. ZHANG S, Song X, Cao D, Xu Z, et al
    Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma induced in mice by AKT and Yap co-expression.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32149.
    >> Share

  789. KOLLY P, Waidmann O, Vermehren J, Moreno C, et al
    Hepatocellular Carcinoma Recurrence after Direct Antiviral Agent Treatment: a European Multicentre Study.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32150.
    >> Share

  790. ROBERTO C, Valeria R, Cristina N, Simona B, et al
    Gut-derived endotoxin stimulates factor viii secretion from endothelial cells. implications for hypercoagulability in cirrhosis.
    J Hepatol. 2017 Jul 14. pii: S0168-8278(17)32145.
    >> Share

  791. FICKERT P, Wagner M
    Biliary bile acids in hepatobiliary injury - What is the link?
    J Hepatol. 2017 Jul 13. pii: S0168-8278(17)32008.
    >> Share

  792. GAVRIILIDIS P, Roberts KJ, Askari A, Sutcliffe RP, et al
    Evaluation of the Current Guidelines for Resection of hepatocellular carcinoma Using the Appraisal of Guidelines Research and Evaluation II Instrument.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32136.
    >> Share

  793. STENGEL S, Stallmach A, Richter K, Landrock A, et al
    Serum metabolic signatures in patients with overt hepatic encephalopathy.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32138.
    >> Share

  794. WEISS N, Colsch B, Fenaille F, Junot C, et al
    Metabolic signature for severe cirrhosis with inflammation or hepatic encephalopathy: do we really face two different entities?
    J Hepatol. 2017 Jul 5. pii: S0168-8278(17)32140.
    >> Share

  795. BRUIX J, Cheng AL, Meinhardt G, Nakajima K, et al
    Prognostic Factors and Predictors of Sorafenib Benefit in Patients With Hepatocellular Carcinoma: Analysis of Two Phase 3 Studies.
    J Hepatol. 2017 Jul 4. pii: S0168-8278(17)32134.
    >> Share

  796. SAMJI H, Yu A, Kuo M, Alavi M, et al
    Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.
    J Hepatol. 2017 Jul 3. pii: S0168-8278(17)32133.
    >> Share

    June 2017
  797. BECK M, Schirmacher P, Singer S
    Alterations of the nuclear transport system in hepatocellular carcinoma - new basis for therapeutic strategies.
    J Hepatol. 2017 Jun 30. pii: S0168-8278(17)32122.
    >> Share

  798. YIP TC, Chan HL, Wong VW, Tse YK, et al
    Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Jun 23. pii: S0168-8278(17)32092.
    >> Share

  799. MARIN V, Poulsen K, Odena G, McMullen MR, et al
    Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32086.
    >> Share

  800. XIANG X, You XM, Zhong JH, Li LQ, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32081.
    >> Share

  801. POORDAD F, Nelson DR, Feld JJ, Fried MW, et al
    Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083.
    >> Share

  802. ARTRU F, Louvet A, Ruiz I, Levesque E, et al
    Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32079.
    >> Share

  803. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    RE: Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32084.
    >> Share

  804. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32074.
    >> Share

  805. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32075.
    >> Share

  806. PANG Q, Liu HC, Zhou L, Jin H, et al
    Inappropriateuse of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32082.
    >> Share

  807. NAGATA H, Nakagawa M, Asahina Y, Sato A, et al
    Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
    J Hepatol. 2017 Jun 13. pii: S0168-8278(17)32070.
    >> Share

  808. KALAMBOKIS GN, Baltayannis G, Christodoulou D, Christou L, et al
    Beta adrenergic blockade and advanced cirrhosis: does it really improve survival in patients with acute-on-chronic liver failure?
    J Hepatol. 2017 Jun 6. pii: S0168-8278(17)32064.
    >> Share

    May 2017
  809. TERATANI T, Tomita K, Suzuki T, Furuhashi H, et al
    Free cholesterol accumulation in liver sinusoidal endothelial cells exacerbates acetaminophen hepatotoxicity via TLR9 signaling.
    J Hepatol. 2017 May 26. pii: S0168-8278(17)32056.
    >> Share

  810. LU Z, Zuo B, Jing R, Gao X, et al
    Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.
    J Hepatol. 2017 May 23. pii: S0168-8278(17)32055.
    >> Share

  811. CALDERARO J, Couchy G, Imbeaud S, Amaddeo G, et al
    Histological Subtypes of Hepatocellular Carcinoma Are Related To Gene Mutations and Molecular Tumour Classification.
    J Hepatol. 2017 May 19. pii: S0168-8278(17)32050.
    >> Share

  812. PEMBROKE T, Deschenes M, Lebouche B, Benmassaoud A, et al
    Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32047.
    >> Share

  813. DE GALARRETA MR, Lujambio A
    Therapeutic editing of hepatocyte genome in vivo.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32048.
    >> Share

  814. ANDREASSON K, Waldenstrom J, Westin J, Norrgren H, et al
    JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32044.
    >> Share

  815. WANG Q, Lv Y, Bai M, Wang Z, et al
    Eight millimeter covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding.
    J Hepatol. 2017 May 12. pii: S0168-8278(17)32015.
    >> Share

  816. ASHHAB AA, Rodin H, Powell J, Debes JD, et al
    Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors don't seem to matter, unless you are an immigrant.
    J Hepatol. 2017 May 10. pii: S0168-8278(17)32012.
    >> Share

  817. SHIN WJ, Hwang GS
    Reply to: "Pressure volume curves in cirrhosis: more than meets the eye".
    J Hepatol. 2017 May 9. pii: S0168-8278(17)32010.
    >> Share

  818. RIPOLL C, Yotti R, Banares R, Bermejo J, et al
    Pressure Volume Curves in Cirrhosis: more than meets the eye.
    J Hepatol. 2017 May 8. pii: S0168-8278(17)32006.
    >> Share

  819. TAN-GARCIA A, Wai LE, Zheng D, Ceccarello E, et al
    Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32004.
    >> Share

  820. LEE S, Kim SH, Lee JE, Sinn DH, et al
    Preoperative Gadoxetic acid-enhanced MRI for Predicting Microvascular Invasion in Patients with Single hepatocellular carcinoma.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32005.
    >> Share

  821. MUELLER J, Raisi H, Rausch V, Peccerella T, et al
    Sensitive and non-invasive assessment of hepatocellular iron using a novel room-temperature susceptometer.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32000.
    >> Share

  822. NADIM MK, DiNorcia J, Ji L, Groshen S, et al
    Inequity In Organ Allocation For Patients Awaiting Liver Transplantation: Rationale for Uncapping the Model for End-Stage Liver Disease.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32003.
    >> Share

  823. VAUTHEY JN, Mizuno T, Overman MJ, Soubrane O, et al
    Can we navigate chemotherapy-induced hepatic injuries from pathology to bedside?
    J Hepatol. 2017 May 2. pii: S0168-8278(17)30252.
    >> Share

  824. MOSCA A, Nobili V, De Vito R, Crudele A, et al
    Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents.
    J Hepatol. 2017;66:1031-1036.
    >> Share

  825. SANDBOTHE M, Buurman R, Reich N, Greiwe L, et al
    The microRNA-449 family inhibits TGF-beta-mediated liver cancer cell migration by targeting SOX4.
    J Hepatol. 2017;66:1012-1021.
    >> Share

  826. KARLAS T, Petroff D, Sasso M, Fan JG, et al
    Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
    J Hepatol. 2017;66:1022-1030.
    >> Share

  827. HUANG K, Du M, Tan X, Yang L, et al
    PARP1-mediated PPARalpha poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    J Hepatol. 2017;66:962-977.
    >> Share

    April 2017
  828. KLINGENBERG M, Matsuda A, Diederichs S, Patel T, et al
    Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30250.
    >> Share

  829. BRITO-AZEVEDO A
    Carvedilol and survival in cirrhosis with ascites: a cognitive bias?
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30219.
    >> Share

  830. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    >> Share

  831. SEIDEL RA, Claudel T, Schleser FA, Ojha NK, et al
    Impact of higher-order heme degradation products on hepatic function and hemodynamics.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30208.
    >> Share

  832. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    >> Share

  833. HASSON H, Merli M, Messina E, Bhoori S, et al
    Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30203.
    >> Share

  834. TAPPER EB, Sengupta N
    Testing for elevated liver enzymes: central to clinical Hepatology but in need of more data.
    J Hepatol. 2017 Apr 6. pii: S0168-8278(17)30199.
    >> Share

  835. CARUSO S, Calderaro J, Letouze E, Nault JC, et al
    Germline and somatic DICER1 mutations in familial and sporadic liver tumors.
    J Hepatol. 2017;66:734-742.
    >> Share

  836. KOPEC AK, Joshi N, Cline-Fedewa H, Wojcicki AV, et al
    Fibrin(ogen) drives repair after acetaminophen-induced liver injury via leukocyte alphaMbeta2 integrin-dependent upregulation of Mmp12.
    J Hepatol. 2017;66:787-797.
    >> Share

  837. WOOLBRIGHT BL, Jaeschke H
    Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure.
    J Hepatol. 2017;66:836-848.
    >> Share

  838. FERRERE G, Wrzosek L, Cailleux F, Turpin W, et al
    Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
    J Hepatol. 2017;66:806-815.
    >> Share

    March 2017
  839. KIM JY, Park KJ, Hwang JY, Kim GH, et al
    Activating Transcription Factor 3 Is a Target Molecule Linking Hepatic Steatosis to Impaired Glucose Homeostasis.
    J Hepatol. 2017 Mar 29. pii: S0168-8278(17)30187.
    >> Share

  840. QURINO L, Massimo R, Jan L
    Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?
    J Hepatol. 2017 Mar 24. pii: S0168-8278(17)30180.
    >> Share

  841. BHAT M, Ghali P, Bilodeau M
    Reply to: "Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?"
    J Hepatol. 2017 Mar 24. pii: S0168-8278(17)30183.
    >> Share

  842. PREZIOSI ME, Singh S, Valore EV, Jung CL, et al
    Mice lacking liver-specific beta-catenin develop steatohepatitis and fibrosis after iron overload.
    J Hepatol. 2017 Mar 21. pii: S0168-8278(17)30146.
    >> Share

  843. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Mar 20. pii: S0168-8278(17)30145.
    >> Share

  844. URBAN TJ, Nicoletti P, Chalasani N, Serrano J, et al
    Minocycline Hepatotoxicity: Clinical characterization and identification of HLA-B * 35:02 as a risk factor.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30144.
    >> Share

  845. HUANG A, Zhao X, Yang XR, Li FQ, et al
    Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30139.
    >> Share

  846. VILARINHO S, Erson-Omay Z, Mitchell-Richards K, Cha C, et al
    Exome Analysis of the Evolutionary Path of Hepatocellular Adenoma-Carcinoma Transition, Vascular Invasion and Brain Dissemination.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30143.
    >> Share

  847. PATOURAUX S, Rousseau D, Bonnafous S, Lebeaupin C, et al
    CD44 is a key player in non-alcoholic steatohepatitis.
    J Hepatol. 2017 Mar 16. pii: S0168-8278(17)30137.
    >> Share

  848. JOSHI D, Gupta N, Samyn M, Deheragoda M, et al
    The management of childhood liver diseases in adulthood.
    J Hepatol. 2017;66:631-644.
    >> Share

  849. LACKNER C, Spindelboeck W, Haybaeck J, Douschan P, et al
    Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease.
    J Hepatol. 2017;66:610-618.
    >> Share

  850. RAMIREZ T, Li YM, Yin S, Xu MJ, et al
    Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression.
    J Hepatol. 2017;66:601-609.
    >> Share

  851. LUKACS-KORNEK V, Lammert F
    The progenitor cell dilemma: Cellular and functional heterogeneity in assistance or escalation of liver injury.
    J Hepatol. 2017;66:619-630.
    >> Share

  852. SPIRLI C, Mariotti V, Villani A, Fabris L, et al
    Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
    J Hepatol. 2017;66:571-580.
    >> Share

  853. LANGIEWICZ M, Schlegel A, Saponara E, Linecker M, et al
    Hedgehog pathway mediates early acceleration of liver regeneration induced by a novel two-staged hepatectomy in mice.
    J Hepatol. 2017;66:560-570.
    >> Share

    February 2017
  854. NAKAGAWA R, Muroyama R, Saeki C, Goto K, et al
    miR-425 regulates inflammatory cytokine production in CD4+ T cells via N-Ras upregulation in primary biliary cholangitis.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30066.
    >> Share

  855. TREBICKA J
    Emergency TIPS in a Child-Pugh B patient: When does the window of opportunity open and close?
    J Hepatol. 2017;66:442-450.